<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C5FD03BC-C39D-4084-B2FE-A38FB9177D1A"><gtr:id>C5FD03BC-C39D-4084-B2FE-A38FB9177D1A</gtr:id><gtr:name>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39B73BF0-6F1A-4F02-9639-60736B28A074"><gtr:id>39B73BF0-6F1A-4F02-9639-60736B28A074</gtr:id><gtr:name>Nye Pluss</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D49A6E9-BF40-4299-915A-1E204BF44D5D"><gtr:id>1D49A6E9-BF40-4299-915A-1E204BF44D5D</gtr:id><gtr:name>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/121A1351-0BDF-4049-996D-13B5E3937333"><gtr:id>121A1351-0BDF-4049-996D-13B5E3937333</gtr:id><gtr:name>San Paolo Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B692BCF2-0F6F-47F4-9CD9-AB35179CD985"><gtr:id>B692BCF2-0F6F-47F4-9CD9-AB35179CD985</gtr:id><gtr:name>St. James's Hospital, Dublin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8AB5107C-18AB-4D38-8CFB-96AD4680EB3D"><gtr:id>8AB5107C-18AB-4D38-8CFB-96AD4680EB3D</gtr:id><gtr:name>UK HIV Vaccine Consortium (UKHVC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/476C28D0-C84A-426C-AA10-48C0CCE16B06"><gtr:id>476C28D0-C84A-426C-AA10-48C0CCE16B06</gtr:id><gtr:name>National Institute for Infectious Diseas</gtr:name><gtr:address><gtr:line1>National Inst. for Infectious Diseases</gtr:line1><gtr:line2>Department of Bacterial Science</gtr:line2><gtr:line3>Shinjuku Ku, Toyama 1 - 23 - 1</gtr:line3><gtr:postCode>162840</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/55AD066E-3431-4A59-AB02-D6FFA3D1DC84"><gtr:id>55AD066E-3431-4A59-AB02-D6FFA3D1DC84</gtr:id><gtr:name>GGD Amsterdam</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75C924D5-5134-4F72-AFFE-AD1655EE48F8"><gtr:id>75C924D5-5134-4F72-AFFE-AD1655EE48F8</gtr:id><gtr:name>FHI 360</gtr:name><gtr:address><gtr:line1>359 Blackwell Street</gtr:line1><gtr:line2>Suite 200</gtr:line2><gtr:postCode>27701</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/97DAD014-E63E-4AAA-84F7-98EAD3B32BDB"><gtr:id>97DAD014-E63E-4AAA-84F7-98EAD3B32BDB</gtr:id><gtr:name>Moscow Regional AIDS Centre</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC75162A-C4F8-497E-AD42-5EEF4C35E48A"><gtr:id>FC75162A-C4F8-497E-AD42-5EEF4C35E48A</gtr:id><gtr:name>Infectious Disease Research Institute (IDRI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E"><gtr:id>D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E</gtr:id><gtr:name>City, University of London</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A32E0CF1-72B8-47D2-A614-D74456F65DFD"><gtr:id>A32E0CF1-72B8-47D2-A614-D74456F65DFD</gtr:id><gtr:name>Positive Voices</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A2A453F-81B2-4B90-B942-A83268D4F47F"><gtr:id>0A2A453F-81B2-4B90-B942-A83268D4F47F</gtr:id><gtr:name>CheckpointLX</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/354391D1-1130-4E18-95B7-D0746C89BE14"><gtr:id>354391D1-1130-4E18-95B7-D0746C89BE14</gtr:id><gtr:name>Guy?s &amp; St Thomas? Charity</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB"><gtr:id>F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB</gtr:id><gtr:name>University of Paris Diderot (Paris 7)</gtr:name><gtr:address><gtr:line1>6th European PCRD</gtr:line1><gtr:line2>13 rue Pierre et Marie Curie</gtr:line2><gtr:postCode>F-75205</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63E44D26-67E6-4BB1-B63E-E2730AE68EB0"><gtr:id>63E44D26-67E6-4BB1-B63E-E2730AE68EB0</gtr:id><gtr:name>Braunschweig University of Technology</gtr:name><gtr:address><gtr:line1>Mendelssohnstr</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/340288BD-BCA1-46AA-BA5C-D85DDA0D29C8"><gtr:id>340288BD-BCA1-46AA-BA5C-D85DDA0D29C8</gtr:id><gtr:name>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C5FD03BC-C39D-4084-B2FE-A38FB9177D1A"><gtr:id>C5FD03BC-C39D-4084-B2FE-A38FB9177D1A</gtr:id><gtr:name>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BDB62FBC-921E-49FF-AD56-909ED429E427"><gtr:id>BDB62FBC-921E-49FF-AD56-909ED429E427</gtr:id><gtr:name>Institute of Tropical Medicine</gtr:name><gtr:address><gtr:line1>Nationalestraat 155</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE"><gtr:id>1F16F444-D5C0-4FB7-ADF1-5E95B4393DCE</gtr:id><gtr:name>IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7A0397DD-E0C6-4EA3-8031-B841D2503C4D"><gtr:id>7A0397DD-E0C6-4EA3-8031-B841D2503C4D</gtr:id><gtr:name>Royal Holloway, University of London</gtr:name><gtr:address><gtr:line1>Egham Hill</gtr:line1><gtr:line4>Egham</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>TW20 0EX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB"><gtr:id>FF638415-5CDD-4BBB-ADC2-43DFB8AE30AB</gtr:id><gtr:name>University College Dublin</gtr:name><gtr:address><gtr:line1>Belfield</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39B73BF0-6F1A-4F02-9639-60736B28A074"><gtr:id>39B73BF0-6F1A-4F02-9639-60736B28A074</gtr:id><gtr:name>Nye Pluss</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D49A6E9-BF40-4299-915A-1E204BF44D5D"><gtr:id>1D49A6E9-BF40-4299-915A-1E204BF44D5D</gtr:id><gtr:name>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/121A1351-0BDF-4049-996D-13B5E3937333"><gtr:id>121A1351-0BDF-4049-996D-13B5E3937333</gtr:id><gtr:name>San Paolo Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B692BCF2-0F6F-47F4-9CD9-AB35179CD985"><gtr:id>B692BCF2-0F6F-47F4-9CD9-AB35179CD985</gtr:id><gtr:name>St. James's Hospital, Dublin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8AB5107C-18AB-4D38-8CFB-96AD4680EB3D"><gtr:id>8AB5107C-18AB-4D38-8CFB-96AD4680EB3D</gtr:id><gtr:name>UK HIV Vaccine Consortium (UKHVC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/476C28D0-C84A-426C-AA10-48C0CCE16B06"><gtr:id>476C28D0-C84A-426C-AA10-48C0CCE16B06</gtr:id><gtr:name>National Institute for Infectious Diseas</gtr:name><gtr:address><gtr:line1>National Inst. for Infectious Diseases</gtr:line1><gtr:line2>Department of Bacterial Science</gtr:line2><gtr:line3>Shinjuku Ku, Toyama 1 - 23 - 1</gtr:line3><gtr:postCode>162840</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/55AD066E-3431-4A59-AB02-D6FFA3D1DC84"><gtr:id>55AD066E-3431-4A59-AB02-D6FFA3D1DC84</gtr:id><gtr:name>GGD Amsterdam</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB"><gtr:id>1C4A24DC-2FF4-47B7-B5FA-46BFF24DF5AB</gtr:id><gtr:name>National Institute for Medical Research</gtr:name><gtr:address><gtr:line1>Ocean Road</gtr:line1><gtr:line2>PO Box 9653</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C754D612-4D8B-42CB-922C-07E7F5BE4B49"><gtr:id>C754D612-4D8B-42CB-922C-07E7F5BE4B49</gtr:id><gtr:name>Washington University in St. Louis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75C924D5-5134-4F72-AFFE-AD1655EE48F8"><gtr:id>75C924D5-5134-4F72-AFFE-AD1655EE48F8</gtr:id><gtr:name>FHI 360</gtr:name><gtr:address><gtr:line1>359 Blackwell Street</gtr:line1><gtr:line2>Suite 200</gtr:line2><gtr:postCode>27701</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/97DAD014-E63E-4AAA-84F7-98EAD3B32BDB"><gtr:id>97DAD014-E63E-4AAA-84F7-98EAD3B32BDB</gtr:id><gtr:name>Moscow Regional AIDS Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC75162A-C4F8-497E-AD42-5EEF4C35E48A"><gtr:id>FC75162A-C4F8-497E-AD42-5EEF4C35E48A</gtr:id><gtr:name>Infectious Disease Research Institute (IDRI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A21478EA-E506-4B64-A8A9-42CD8D97C635"><gtr:id>A21478EA-E506-4B64-A8A9-42CD8D97C635</gtr:id><gtr:name>University College London Hospital (UCLH) NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67B34D05-3A52-4A09-8FF9-F2398D60E246"><gtr:id>67B34D05-3A52-4A09-8FF9-F2398D60E246</gtr:id><gtr:name>University of Surrey</gtr:name><gtr:address><gtr:line1>Registry</gtr:line1><gtr:line2>Stag Hill</gtr:line2><gtr:line4>Guildford</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU2 7XH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E"><gtr:id>D394BCC7-2CE9-41C0-A124-1A05C8E4FD6E</gtr:id><gtr:name>City, University of London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39147180-4991-4D6E-A137-E473AB40A04E"><gtr:id>39147180-4991-4D6E-A137-E473AB40A04E</gtr:id><gtr:name>International AIDS Vaccine Initiative (IAVI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A32E0CF1-72B8-47D2-A614-D74456F65DFD"><gtr:id>A32E0CF1-72B8-47D2-A614-D74456F65DFD</gtr:id><gtr:name>Positive Voices</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A2A453F-81B2-4B90-B942-A83268D4F47F"><gtr:id>0A2A453F-81B2-4B90-B942-A83268D4F47F</gtr:id><gtr:name>CheckpointLX</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2B4890EC-5704-4F99-AE13-CC1371378CBB"><gtr:id>2B4890EC-5704-4F99-AE13-CC1371378CBB</gtr:id><gtr:name>Copenhagen University Hospital</gtr:name><gtr:address><gtr:line1>Kettegaard Alle 30</gtr:line1><gtr:postCode>DK-2650</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/354391D1-1130-4E18-95B7-D0746C89BE14"><gtr:id>354391D1-1130-4E18-95B7-D0746C89BE14</gtr:id><gtr:name>Guy?s &amp; St Thomas? Charity</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB"><gtr:id>F128C1F3-340C-4C0B-9BD0-93B2CEFF81BB</gtr:id><gtr:name>University of Paris Diderot (Paris 7)</gtr:name><gtr:address><gtr:line1>6th European PCRD</gtr:line1><gtr:line2>13 rue Pierre et Marie Curie</gtr:line2><gtr:postCode>F-75205</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1"><gtr:id>680A2524-B8AD-4E19-ACD2-3EECFCC5DAF1</gtr:id><gtr:name>Hull York Medical School</gtr:name><gtr:address><gtr:line1>John Hughlings Jackson Building</gtr:line1><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36FCE8DD-97CB-47E6-A1E8-AE17410DD826"><gtr:id>36FCE8DD-97CB-47E6-A1E8-AE17410DD826</gtr:id><gtr:name>Government of Sweden</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/421AD70F-9A6E-48CE-9C42-6C508F1FBAD8"><gtr:id>421AD70F-9A6E-48CE-9C42-6C508F1FBAD8</gtr:id><gtr:name>Eastern Virginia Medical School (EVMS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7B2F79C-C794-4597-898F-93292A2B77A3"><gtr:id>C7B2F79C-C794-4597-898F-93292A2B77A3</gtr:id><gtr:name>Fit Biotech Oy</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63E44D26-67E6-4BB1-B63E-E2730AE68EB0"><gtr:id>63E44D26-67E6-4BB1-B63E-E2730AE68EB0</gtr:id><gtr:name>Braunschweig University of Technology</gtr:name><gtr:address><gtr:line1>Mendelssohnstr</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7E3C0045-B615-48B0-B761-74896FEED7ED"><gtr:id>7E3C0045-B615-48B0-B761-74896FEED7ED</gtr:id><gtr:firstName>Sheena</gtr:firstName><gtr:surname>McCormack</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F1"><gtr:id>334596F1-9665-4B5E-8CDA-B21F92E192CF</gtr:id><gtr:title>Prevention Programme - Microbicides.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/1</gtr:grantReference><gtr:abstractText>The focus of this programme is to develop female controlled methods to prevent HIV which are safe, effective and affordable. |This large project brings together several experts in a partnership across Europe and Africa in the microbicide field. A microbicide is a product used vaginally to prevent infection by HIV or other sexually transmitted infections (STIs). A particular microbicide (PRO 2000/5) was selected after being tested in the laboratory and tested for safety. Once found to be safe, studies were undertaken by African partners to prepare for a large trial. This multi-centre Phase III trial began in October 2005 and recruitment closed in August 2008. 9385 women were enrolled from the following sub-Saharan African sites, in South Africa (Johannesburg, Soweto and Orange Farm, Durban, Tongaat, Verulam Isipingo, Africa Centre), Tanzania (Mwanza), Uganda (Masaka), Zambia (Mazabuka). The last visit took place in September 2009. Unfortunately, we demonstrated conclusively that PRO 2000/5 vaginal gel did not prevent HIV infection. This was disappointing as promising results were reported earlier in 2009 in an independent smaller trial, which we now know were due to chance.|We are now concentrating on the more potent anti-retroviral microbicides (anti-retrovirals are specific for HIV and used for treatment).</gtr:abstractText><gtr:technicalSummary>The focus of this programme is to develop female controlled methods to prevent HIV which are safe, effective and affordable. |In the absence of an effective vaccine to prevent the spread of HIV-infection and the continuing HIV pandemic, which is particularly devastating in sub-Saharan Africa there is an urgent need to develop alternative methods of prevention. Women in sub-Saharan Africa are particularly vulnerable being unable in most instances to negotiate the use of condoms with their partners. |A central objective is the development and clinical assessment of candidate microbicides for the prevention of vaginally acquired HIV infection. The CTU is jointly co-ordinating the multi-disciplinary Microbicides Development Programme with Imperial College at St Marys Hospital, London.||The initial work focused on testing the safety of 2 candidate microbicides both in Europe (Antwerp and the UK) and in Africa (Uganda). In parallel to these trials, Feasibility studies were conducted in 6 African sites, to inform the design and size of a Phase 3 trial to assess two active products. A short Pilot study using placebo gel was conducted to validate the procedures planned for the main trial, and a final evaluation of the pre-clinical and clinical data was performed in August 2004 to select the product and concentration. A large Phase 3 trial of low and hig dose PRO 2000/5 vaginal gel began recruiting in 2005. CTU coordinated the development of the protocol, case record forms, database, monitoring, analyses and oversight (Trial Management Group, Trial Steering Committee and Data and Safety Monitoring Committee meetings).||Between October 2005 and August 2008 9385 women were enrolled from the following sub-Saharan African sites, in South Africa (Johannesburg, Soweto and Orange Farm, Durban, Tongaat, Verulam and Isipingo, Africa Centre), Tanzania (Mwanza), Uganda (Masaka), and Zambia (Mazabuka). Women were followed for at least 12 months (up to 24months in Uganda) and were asked to insert the gel pre-sex.||The trial assessed two doses of PRO2000/5 (2% and 0.5%) each in comparison with a placebo. In February 2008 the 2% gel was discontinued on the recommendation of the Independent Data Monitoring Committee as there was no more than a small chance of demonstrating benefit according to the original statistical plan.||Recruitment closed on the 15th of August 2008 and follow up will continue until August 2009. The study database was locked on the 1st November 2009 and the results were reviewed by the Senior Investigators, Trial Steering and Independent Data Monitoring Committees as well as two independent referees appointed by MRC prior to release of the result in December 2009. Unfortunately neither 0.5% nor 2% PRO 2000/5 reduced the incidence of HIV when compared to placebo gel.||The next scientific questions are focused around the more potent anti-retroviral microbicides, and MDP is preparing for the results of the CAPRISA 004 trial of tenofovir 1% vaginal gel which will report in July 2010. In anticipation of significant but moderate protection we are conducting a further pilot of daily placebo gel, the Top-Up study in 5 sub-Saharan countries: Uganda (Masaka), Tanzania (Mwanza), South Africa (Durban), and Zambia (Mazabuka) all of which participated in the Phase 3 trial, plus Mozambique (Maputo and Manhica) where they have successfully completed a Feasibility study. Three methods of collecting in the used applicators are being explored: daily, weekly and every 4 weeks at the clinic visits. Top-Up has been enrolling since June 2010 and is expected to report early 2011.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>971000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>An explanatory video has been produced with the aim of presenting the CHAARM project and its main goal. It explains what are microbicides and it shows why is important to develop alternative prevention methods, such as new combination of microbicides, for controlling the risk of HIV infection. Professor Sheena McCormack is featured in the video.</gtr:description><gtr:id>1F8FEA3D-C488-49BD-A4DB-9989CA2A09C2</gtr:id><gtr:impact>This film aimed to increase the profile of microbicides in Europe.</gtr:impact><gtr:outcomeId>545a6329a506f6.73173682</gtr:outcomeId><gtr:title>CHAARM video filming - 28th April 2014</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://chaarm.eu/content/newsroom</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>This was a documentary created by students and built around the personal experience of a close friend of theirs who had recently been diagnosed with HIV and who was considering participation in a research study.</gtr:description><gtr:id>2E81E568-36F0-45E2-98EC-BE2DF56B05A1</gtr:id><gtr:impact>The film was well received at the graduation ceremony.</gtr:impact><gtr:outcomeId>545a62b8127631.50981537</gtr:outcomeId><gtr:title>Filming for Goldsmith's University BA Media student graduation documentary, 13th Jan. 2014</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>Multi-artistic product which was created by John Walter who is funded by Wellcome Trust to do a PhD.
The exhibition is entitled the Alien Sex Club and there were two main exhibitions, one in London and one in Liverpool.</gtr:description><gtr:id>0F2B7665-3126-4157-9564-E9B5473EA305</gtr:id><gtr:impact>Raising awareness of HIV, STIs, PrEP</gtr:impact><gtr:outcomeId>566702a9ba9e30.40466294</gtr:outcomeId><gtr:title>Alien Sex Club Exhibition, Liverpool, 21st Nov. 2015 - event artist Susanna Hewlett, event scientist Prof. Sheena McCormack</gtr:title><gtr:type>Artistic/Creative Exhibition</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>Professor Sheena McCormack featured in the video 'The Gold Standard: What are randomised controlled trials and why are they important?' available at http://www.ctu.mrc.ac.uk/resources/multimedia/</gtr:description><gtr:id>1D7CAFD9-7A49-4819-8C8C-819C7972D9D4</gtr:id><gtr:impact>The film aimed to broaden understanding of clinical trials for lay and non-expert audiences.</gtr:impact><gtr:outcomeId>545a640f1cfa16.18724393</gtr:outcomeId><gtr:title>Contribution to video filming to feature on MRC CTU at UCL website</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://www.ctu.mrc.ac.uk/resources/multimedia/</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput><gtr:artisticAndCreativeProductOutput><gtr:description>PROUD documentary and Voices of Participants premiere, The Cinema Museum, SE11, London. Launched 1st July 2015</gtr:description><gtr:id>3029F577-321D-48A9-BA86-64117B19066B</gtr:id><gtr:impact>Raising awareness of PrEP amongst gay men and promoting debate.
The film was also produced for German audiences with subtitles.</gtr:impact><gtr:outcomeId>56be1c36e1d6a9.43923495</gtr:outcomeId><gtr:title>PROUD documentary and Voices of Participants premiere 1st July 2015, The Cinema Museum, SE11, London.</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>https://vimeo.com/132412294</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM U543 (Cellular and Tissue Immunology Laboratory)</gtr:department><gtr:description>CutHivac</gtr:description><gtr:id>2EBCC1D9-B4C8-4570-B2A8-0240F5E47C6F</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-1</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>02E3F06B-077A-4CB9-8DB4-7B630E5D5D39</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-6</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Surrey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>C2F94EFA-F039-44AA-A1CD-7DA3E3C3B3FB</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-3</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>School of Medicine and Medical Science</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>2553DB01-5CFC-400E-AD2A-1994ECD123DB</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-4</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Inserm Transfert</gtr:department><gtr:description>European HIV Vaccine Alliance (EHVA)</gtr:description><gtr:id>72B05FC7-2791-4683-B0CE-ECC04D885A26</gtr:id><gtr:impact>Trial protocols currently in development. Attendance at launch meeting and work package meetings/teleconferences.
This is a multi-disciplinary collaboration.</gtr:impact><gtr:outcomeId>56df117ccbada7.69195512-1</gtr:outcomeId><gtr:partnerContribution>Amongst the 39 partners within the collaboration, there is expertise in immunology, virology, structural biology, viral vectors, statistics, computational and clinical science.

Specific objectives within the collaboration are to build up as below, a:
1) Discovery platform - generation of novel vaccine candidates in the field of prophylactic and therapeutic vaccines inducing potent neutralizing and non-neutralizing antibody and T-cell responses.

2) Immune profiling platform - to rank novel and benchmark existing vaccine candidates in pre-clinical and human clinical trials through validated, qualified and standardized immunological assays and using advanced technologies in the profiling of the immune responses.

3) Data Management/Integration/Down-Selection Platform - to provide powerful statistical tools for the analysis and interpretation of complex data and algorithms for the selection of vaccine candidates at different stages of pre-clinical and clinical vaccine development.

2) Clinical trials platform - the primary goal is the acceleration of clinical development of novel vaccine candidates and the early prediction of failure of vaccine candidates.</gtr:partnerContribution><gtr:piContribution>39 partners have signed a research collaboration agreement (European Commission funded project 1st Jan 2016-31st Dec 2020).
The EHVA program will develop a multidisciplinary vaccine platform (MVP) in the fields of prophylactic and therapeutic vaccines
Trial protocols currently in development. Attendance at launch meeting and workpackage meetings/teleconferences.
CTU providing trial management and statistical support.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Tropical Medicine Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>7B3838D9-C0FA-4C55-B827-6552FE36E2D8</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-2</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muhimbili University of Health and Allied Sciences</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>Department of Microbiology and Immunology</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>6863C4C5-D078-47D7-98EA-287402625A49</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-1</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>E10C6140-0E9C-4D2A-924B-04A9B2FAED38</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-1</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>ADD30E8A-20DE-474F-83FD-A613ABEF9077</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-3</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>FE2058AB-FF84-4F6D-8590-C07E401CA1FE</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-5</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>August Pi i Sunyer Biomedical Research Institute (IDIBAPS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Hospital Clinic of Barcelona</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>07081041-F664-455B-9452-6B1AC3D83590</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-16</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UK HIV Vaccine Consortium (UKHVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr. Sarah Joseph collaboration with Chriss Geldmacher: Epitope mapping project</gtr:description><gtr:id>CDE13981-78A1-4D1F-A1E5-42AC551CF4F0</gtr:id><gtr:impact>Preliminary results presented data to UKHVC - analysis ongoing</gtr:impact><gtr:outcomeId>5464a68646b457.63631989-2</gtr:outcomeId><gtr:partnerContribution>Expert in the technology needed for the project. Major financial contribution to the project.</gtr:partnerContribution><gtr:piContribution>Jointing drafted the application and contributed to the design of the study.
UKHVC supplied samples for cross comparison studies between other trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>DBA71009-4283-42E3-ADFA-FA213E01CFBA</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-4</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Immunology</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:id>76B367C6-4832-44A5-B4B1-3063520588B5</gtr:id><gtr:impact>Bioinformatice Analysis is ongoing and will lead to publication and strengthening of infrastructure and expertise within the consortium.</gtr:impact><gtr:outcomeId>aUhNHqNH37L-1</gtr:outcomeId><gtr:partnerContribution>Unversity of Munich supplied man power and also access to samples from vaccinated and chronically infected individuals for deep sequencing. The facility at Helmholtz supplied access to deep sequencing technology and expertise.</gtr:partnerContribution><gtr:piContribution>Sarah Joseph was a lead applicant on an application made to TRANSVAC for access to deep sequencing technology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paris Diderot University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>E9B09EDD-90B1-477A-91DE-617C51CB4D3B</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-1</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fit Biotech Oy</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>4CD87F23-D746-4D2E-88FE-8DC93A243697</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-3</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portuguese Group of Activists Treatments for HIV/AIDS Pedro Santos (GAT)</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>7532F366-ABDB-42FA-A08B-2296896368B4</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-7</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>575CA139-5835-430D-8F67-1AAD235F2AD5</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-1</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Holloway, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>4CA19BC7-197B-4293-B926-CADFE5F75BF1</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-3</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>San Paolo Hospital</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>01CE1937-0B08-4134-81D7-7EBE0BAAB8DB</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-12</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>City, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>120782B9-6BB1-4763-B315-F52122F6F613</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-2</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Positive Voices</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>C876B184-95E1-447C-A346-42012CF25DDE</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-11</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Infectious Disease Research Institute (IDRI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>970A85E1-5317-4013-8ADC-668D2B0A38C5</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-2</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FHI 360</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Hormonal contraception and risk of HIV acquistion: individual participant data analysis</gtr:description><gtr:id>7E40E032-F069-47D2-886E-6DF395D8E0E1</gtr:id><gtr:impact>An oral presentation at CROI 2014 and a manuscript which has been submitted. The analysis will be used by WHO when considering the next revision to their guidelines.</gtr:impact><gtr:outcomeId>546248de2fc527.82139755-1</gtr:outcomeId><gtr:partnerContribution>Import of the data and analysis using marginal structural models.</gtr:partnerContribution><gtr:piContribution>We provided data from the MDP301 dataset to the team at FHI as part of the individual participant data analysis to assess the association between hormonal contraception and the acquisition of HIV. As MDP301 was the largest dataset (over 8000 women) it was very influential. The Trial Statistician for MDP301 had to prepare the dataset for export.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Praxis Jessen2 and Kollegen</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>4FBE102F-72CB-41F3-A126-06F80F5272E7</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-10</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Sweden</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Swedish Institute for Infectious Disease Control (Smittskyddsinstitutet SMI/SIIDC)</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>72224ECB-CAF1-447E-A42D-233D6E62E79F</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-2</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>940C6605-FD53-4F56-B0C1-7C85E9F236F8</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-7</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>35BDCAFC-55C8-4049-9C78-2FA9971BE428</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-7</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Medicine</gtr:department><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>5C60A1D0-07CB-44E5-B11B-D8131E35D238</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-1</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy?s &amp; St Thomas? Charity</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HOME PEPSE: 'The role of home packs of HIV post-exposure prophylaxis for sexual exposure to improve the speed and appropriate uptake of PEPSE in high risk individuals' (Guy's and St. Thomas's NHS Foundation Trust)</gtr:description><gtr:id>705FEA42-5EF3-4BFE-88E9-A274545D4359</gtr:id><gtr:impact>CTU social scientist to work more fully on this project during 2016.</gtr:impact><gtr:outcomeId>56df39c0259682.32114229-1</gtr:outcomeId><gtr:partnerContribution>St. Thomas's through Dr. Julie Fox, have designed the research protocol are taking the lead in managing the trial.</gtr:partnerContribution><gtr:piContribution>CTU role through our PROUD trial Social Scientist will be to conduct in depth interviews in a participant sub-set and probe for barriers and facilitators to reducing the risk of HIV, determine perceptions of risk and PEPSE need and check that the participant understands the evidence provided regarding effectiveness.

Interviews will be with MSM about their experiences in the HOME PEPSE study. Qualitative audio file recordings (written participant consent to be gained prior to data collection) will be imported into NVivo, a qualitative data analysis package and coded using a combination of audio and transcribed textual coding using a predefined coding framework.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>DD5B1C6C-ABD7-4E93-AE3E-F8A229222A13</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-4</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull York Medical School</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>BB3AFA7C-554F-4B77-990E-3D483F65BDDA</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-2</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>BB3B6EF9-D851-46AF-B4A1-41E10819B447</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-5</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Cellular and Molecular Medicine</gtr:department><gtr:description>MucoVac 2</gtr:description><gtr:id>5578A81A-3327-4A19-AC1A-91380AE27C11</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-1</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Medical Research, Tanzania</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:description>TamoVac II</gtr:description><gtr:id>AABFF392-D7FA-4ACC-BBC9-23B2810BB088</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-4</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nye Pluss</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>99EA653C-73C2-4AAE-95FE-B5F4D941D295</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-13</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eastern Virginia Medical School (EVMS)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Contraception Research and Development (CONRAD)</gtr:department><gtr:description>Microbicides Development Programme (MDP) and CONRAD tenofovir project</gtr:description><gtr:id>EF030B73-5799-4357-9DEB-0A1C00C10191</gtr:id><gtr:impact>Full funding application to EDCTP 15th March 2016, but not funded.</gtr:impact><gtr:outcomeId>54623574017df4.16347308-1</gtr:outcomeId><gtr:partnerContribution>CONRAD invited Professor Sheena McCormack to develop research proposals for CONRAD's Microbicide APS Objective 1 (MAPS1) which was successfully funded</gtr:partnerContribution><gtr:piContribution>Our research team developed research proposals to conduct a phase II clinical trial of tenofovir gel in either vaginal ring or tablet form, and an open-label wait listed design of tenofovir gel with Microbicides Development Programme partners in Uganda and Mozambique. 

Funding application currently being drafted for submission to EDCTP by 15th March 2016: 'A pragmatic, randomised open-label wait-listed trial to evaluate the effectiveness of tenofovir to reduce the risk of HIV acquisition among women involved in transactional and commercial sex in Mozambique, Rwanda, Tanzania and Uganda.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UK HIV Vaccine Consortium (UKHVC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MucoVac 2</gtr:description><gtr:id>845EBFF8-7B10-4F2C-839A-1AE4D2484AE9</gtr:id><gtr:impact>Trial protocol, CRF and database. 
Clinical study report.
Paper in presentation.</gtr:impact><gtr:outcomeId>kJqZu4bRLi7-3</gtr:outcomeId><gtr:partnerContribution>Provision of Clinical and laboratory facilities/staff for clincial trial. Responsibility for drafting reports and manuscripts. Trial sponsorship (SGUL) Coordination of drafting of trial protocol. Logistical and administrative support. Provision of product and collation of investigator brochure. Collation of submission to MHRA. Immunological analyses (Imperial).</gtr:partnerContribution><gtr:piContribution>Design of clinical trial, CRF, database and supporting documentation. Significant intellectual input into the drafting of the protocol. Co-ordination of networking between UKHVC (product), Helpmakehistory (volunteers). Responsibility for design of monitoring plan, monitoring of trial and preparation of relevant reports. Development of analysis plan and conducting analyses. Co-ordination of final report. Co-ordination of trial management.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial Clinical Trials Unit (ICTU)</gtr:department><gtr:description>AfreVacc I</gtr:description><gtr:id>AB7F56DC-C62C-471A-AB27-4878D4FC8F89</gtr:id><gtr:impact>Protocols approved for feasibility studies in South Africa, Mozambique and Tanzania. Contribution to creation of free access on line database for centralised data capture. Harmonisation of AfreVacc and TamoVac and UKHVC networks in order to add a gp140 protein boost to existing regimen of DNA and MVA in TaMoVac 01 trial.
AfrEVac trial was conducted as an amendment to TaMoVac 01 contributing a recombinant protein boost to participants already primed with DNA/MVA. this was the first time the three HIV immunogens were combined and the strategy is one that we hope to test for efficacy, subject to funding.</gtr:impact><gtr:outcomeId>UyG589LxUWv-1</gtr:outcomeId><gtr:partnerContribution>Logistical and project management, Co-ordination of monthly calls, Planning and organisation of annual investigator meetings, Collation of 6 monthly and annual reports. Co-ordination of training, Integration of other networks, submission of applications for no cost extension</gtr:partnerContribution><gtr:piContribution>Significant intellectual input into the establishment of a new network devoted to HIV vaccine development in the South harnessing the best methodologies and using constructs developed and taken to Phase I/II trials in Europe by the EuroVacc foundation, Significant intellectual input into builiding vaccine trial capacity in South Africa, Tanzania and Mozambique initially by purusing feasibility studies in at risk populations, sharing of exisiting data and expertise in the drafting of protocols and relevant documentation, contributions to design of clinical trials and studies, provision of appropriate training in all aspects of trial design and management, overall responsibility for the management of the trial and drafting of relevant documentation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GGD Amsterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>B1924E6A-3527-40A1-BA04-4F0AB164C0CF</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-5</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Infectious Diseases (Lazzaro Spallanzani IRCCS)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Epidemiology</gtr:department><gtr:description>European PrEP Group</gtr:description><gtr:id>30E5291B-36BB-43CD-8175-6F7068F55294</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-3</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>F7E42641-FEC9-4866-B8E6-BF15C9F63318</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-2</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>45FC7075-FF5A-4943-BBDF-D3CD84540A92</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-5</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>ED2C6022-F842-49A6-9B2E-8B6DCF6D9405</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-6</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Braunschweig University of Technology</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Helmholtz-Zentrum f?r Infektionsforschung</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:id>D7426D80-5B60-4E8C-BE21-71B75E3DE073</gtr:id><gtr:impact>Bioinformatice Analysis is ongoing and will lead to publication and strengthening of infrastructure and expertise within the consortium.</gtr:impact><gtr:outcomeId>aUhNHqNH37L-2</gtr:outcomeId><gtr:partnerContribution>Unversity of Munich supplied man power and also access to samples from vaccinated and chronically infected individuals for deep sequencing. The facility at Helmholtz supplied access to deep sequencing technology and expertise.</gtr:partnerContribution><gtr:piContribution>Sarah Joseph was a lead applicant on an application made to TRANSVAC for access to deep sequencing technology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health, Mozambique (Instituto Nacional de Sa?de)</gtr:collaboratingOrganisation><gtr:country>Mozambique, Republic of</gtr:country><gtr:description>CutHivac</gtr:description><gtr:id>EAA73C91-1CB4-43C9-A1B2-626E2D6170F7</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-6</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International AIDS Vaccine Initiative (IAVI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Human Immunology Laboratory, ICL</gtr:department><gtr:description>UKHVC spoke 03 (MRC DCS scheme)</gtr:description><gtr:id>0E353B30-1588-48B4-A2C0-214A4DA71673</gtr:id><gtr:impact>Spoke 03 trial is fully recruited, completed and reported (see publications).</gtr:impact><gtr:outcomeId>JQh8Yjoazh2-4</gtr:outcomeId><gtr:partnerContribution>University of Surrey/Imperial College: recruitment and follow up of trial participants.
Trial management &amp;amp; analysis: Imperial College, with oversight/input from the MRC Clinical Trials Unit at UCL.</gtr:partnerContribution><gtr:piContribution>Oversight of clinical trial management and statistical analysis. Attendance at regular trial management group teleconferences.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St. James's Hospital, Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>C5395556-B5E6-4B3F-AD58-2913911D51CE</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-8</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PANTHEON: A comprehensive assessment of the cost-effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK</gtr:description><gtr:id>B88BE6D6-EC32-4053-B726-A10995A9D4C8</gtr:id><gtr:impact>Contract signature of partners. Discussions surrounding study database, recruitment and analysis.

Funding provided by NIHR.</gtr:impact><gtr:outcomeId>54563df63d6f45.17849825-4</gtr:outcomeId><gtr:partnerContribution>The partners contribute to the qualitative data collection, the mathematical modelling and the health economics as wel as clinical and community expertise.</gtr:partnerContribution><gtr:piContribution>We have contributed to the clinical trial methodology.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Washington</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>IMPACTA Peru Clinical Trials Unit</gtr:department><gtr:description>CutHivac</gtr:description><gtr:id>9CB4E40E-2151-4B8E-A4E3-818673DF05D6</gtr:id><gtr:impact>CutHivac001 a Phase I trial exploring the use of a novel mode of (prophylactic) vaccination in healthy volunteers fully enrolled (30 participants) in 2014, complete in 2015 and reported at two conferences: BHIVA 2016 and R4P 2016. Manuscript ready for submission.
CUHTHIVTHER a Phase II HIV therapeutic vaccine trial exploring different routes for delivering a DNA vaccine including transcutaneous and intramuscular with electroporation. 
Fully enrolled (30 participants) and completed in 2016. Clinical Study Report submitted to Sponsor, immunology complete and manuscript in draft.
CutHivac002 trials a Phase I prophylactic HIV vaccine trial exploring combination regimens with electroporation is underway and expected to complete in 2017.</gtr:impact><gtr:outcomeId>Lj9jG3qYyqz-7</gtr:outcomeId><gtr:partnerContribution>Co-ordination of the network activities via regular TC and annual investigator meetings. Collation of interim and annual reports. Integration of workpackages.</gtr:partnerContribution><gtr:piContribution>Responsibility for design of trial, analysis plan, drafting of protocol, harmonisation of data generated from other trials within network.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Copenhagen University Hospital</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>776FCFFD-168A-4649-918C-11C2C0AFCAD8</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-9</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Medical Research, Tanzania</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>NIMR Mbeya Research Centre (Formerly known as; Mbeya Medical Research Programme, MMPR)</gtr:department><gtr:description>TamoVac II</gtr:description><gtr:id>2B1D6E84-A41A-4CF8-9448-12862D8D3A03</gtr:id><gtr:impact>Protocol, CRF, data management documentation including analysis plan, database validation and all that is required for a robust data management system.
Analysis workshop at MRC resulted in final analysis plan for TM 01 and design of TaMoVac II.
TaMoVac II completed; Clinical Study Report and manuscript in draft.</gtr:impact><gtr:outcomeId>qLPWvWDq3m7-3</gtr:outcomeId><gtr:partnerContribution>Provision of DNA and MVA. Sponsorship. Data management and statistical analysis. Building vaccine trial capacity in Tanzania and Mozambique by continued support and training to laboratory personnel to explore the responses to DNA priming and MVA boosting strategies. Co-ordination of the grant and organisation of annual investigator meetings.</gtr:partnerContribution><gtr:piContribution>Intellectual input into design of epidemiological studies preceding the trial, design of the trial, data management, analysis plan, CRF, drafting of protocol. Responsibility for coordination of monthly oversight, review of safety, overseeing the monitoring of clinical sites. Participation in annual investigator meetings.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK HIV Vaccine Consortium</gtr:description><gtr:id>F23395DE-A3C5-4842-800B-88002B8084BE</gtr:id><gtr:impact>GMP material for clinical trials manufactured and procured with due diligence on intellectual property.
Annual UK HIV vaccine scientist meeting to review progress and comment on proposals, including meeting in March 2015 to determine whether or not to proceed to efficacy testing of current products.
Several clinical trials that were being conducted in our networks were provided partial support that facilitated completion and full analyses including CUTHIVAC and TaMoVac trials.</gtr:impact><gtr:outcomeId>hVGxkdxs6Zn-2</gtr:outcomeId><gtr:partnerContribution>Intellectual contributions to the design of trials, oversight and provision of GMP and supporting documentation such as the Investigator Brochure, provision of clinical facilities and expert personnel to conduct Phase I HIV vaccine trials, central coordination of the administrative aspects of the award.</gtr:partnerContribution><gtr:piContribution>Design including sample size rationale, drafting complementary grant applications, protocols, CRFs, trial documentation including analysis plan and submissions to competent authority, designing the central database, extracting and analysing data, preparing reports including the final Clinical Study Report.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>CheckpointLX</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>B8D5836E-BCC7-4358-8858-AA800C20668D</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-14</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moscow Regional AIDS Centre</gtr:collaboratingOrganisation><gtr:country>Russian Federation</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>9D4A4C8D-29A8-4246-A4A4-D11C8844EE9B</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-15</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>European PrEP Group</gtr:description><gtr:id>D46B8B62-9A8B-4323-8001-E1A3970298D9</gtr:id><gtr:impact>Up to date knowledge of PrEP activities in Europe including sharing tools and data, and coordination of efforts on advocacy.
Notes of teleconference calls.</gtr:impact><gtr:outcomeId>54624b5182ae67.82572132-6</gtr:outcomeId><gtr:partnerContribution>Ongoing PrEP related activities such as surveys amongst potential users and providers, advocacy, policy.</gtr:partnerContribution><gtr:piContribution>I coordinate this group which convenes quarterly by teleconference to provide an update of PrEP related activities in several European countries: Belgium, Denmark, France, Germany, Greece, Ireland, Italy, the Netherlands, Norway, Portugal, Russia, Spain and the UK.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Use of Social Media for recruitment to HIV prevention research projects: Cuthivac 01 trial</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F9BCCA7C-CDD2-4289-AB5A-F218D42A1E60</gtr:id><gtr:impact>Use of Twitter and Facebook for information sharing and to stimulate recruitment to the Cuthivac 01 vaccine study.

An increase in enquiries. Both studies now fully enrolled.</gtr:impact><gtr:outcomeId>5460e684b39833.17652083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview with The Times for article: Coming soon: the daily pill that can protect against HIV; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1AEEEDDF-A055-4A46-A444-B6702FA8C79A</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fb3072d951.70131820</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thetimes.co.uk/tto/health/news/article4239078.ece</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference on Retroviruses and Opportunistic Infections (CROI), Boston , USA 22-25 Feb 2016. Presentation 'STI control in the era of PrEP' given by Prof. Sheena McCormack</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A661BA01-9EF2-48DE-B11A-BDBD104EE015</gtr:id><gtr:impact>An opportunity to emphasise that other sexually transmitted infections were increasing prior to PrEP introduction due to social changes. PrEP offers the chance to improve control of other STIs through regular screening, early diagnosis, prompt treatment and enhanced contact tracing of partners. 

The Symposium Title was 'Innovations in PrEP.'</gtr:impact><gtr:outcomeId>56dc55eb00b970.15829029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.croiwebcasts.org/console/player/29561?mediaType=podiumVideo&amp;</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>#trialsmatter Twitter Q&amp;A, 20th May 2015</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E473F09E-AB35-476D-ABEA-C83AD29B1C6F</gtr:id><gtr:impact>Q&amp;amp;A on International Clinical Trials day. As well as a range of trialists there were participant/patients and community organisation representatives answering questions as quickly as possible!
#trialsmatter Twitter Q&amp;amp;A, 20th May 2015</gtr:impact><gtr:outcomeId>56bcafa10405e1.15569054</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Italian Conference on AIDS, Riccione, Italy, 17-19.05.15. Prof. McCormack invited  to give a lecture on PROUD results and to participate to a Round Table: 'PrEP: is it the right time to act?'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED54CA72-AA32-4F37-9A87-28B277DA5F10</gtr:id><gtr:impact>Discussion (in Italian with translation) revealed support from clinicians and community for PrEP but difficulties in navigating the current Italian system in which prevention services in general are under-resourced and seemingly not a government priority.</gtr:impact><gtr:outcomeId>56bcb1afd0d940.91718786</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Sheena McCormack participation in a 'HIV in Europe' meeting, 9-11 Dec 2015, Wilton Park, UK</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B040FD3E-70AF-4801-B0EC-ED46C48B4EFC</gtr:id><gtr:impact>The intended purpose was to identify barriers to access to prevention and treatment services for HIV in order to tackle the rising epidemic of HIV in Europe.
Prof. Sheena McCormack spoke on PrEP within session 3 of the programme 'Policy and programme implications for a new era of HIV treatment and prevention.'</gtr:impact><gtr:outcomeId>56dc4febabb616.59878115</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Victoria Derbyshire show, Prof. Sheena McCormack and Yusef Azad (NAT) interview on PrEP and NHS commissioning, 7th June 2016</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C515A625-535C-43AE-A7D3-5481EEC83086</gtr:id><gtr:impact>Victoria Derbyshire show interview with Sheena &amp;amp; Yusef Azad (National AIDS Trust) regarding PrEP, announcement by NHS that they were not the commissioner and NAT's decision to take NHS to court, 7th June 2016</gtr:impact><gtr:outcomeId>57ea9bad23a846.31250532</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media: DW.DE Radio: Truvada Trials (27th November 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2DEB42AD-CD16-4E08-82D5-397AA86D52E3</gtr:id><gtr:impact>Increased awareness of PrEP - PROUD and IPERGAY

No impact yet</gtr:impact><gtr:outcomeId>5476f4373f4643.13584685</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dw.de/program/s-1452-9798</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media: Boyz article titled 'PrEP Up' 27 November 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F7F79B60-2386-4BA4-9E35-755F848848BC</gtr:id><gtr:impact>The article increased awareness of PrEP

No impact to date</gtr:impact><gtr:outcomeId>547340dd320982.18486745</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.joomag.com/magazine/boyz-magazine-1213/0609721001417000705?short</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Extensive enagement with media (radio, TV, online and print) for distribution of PROUD trial results, February 2015</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>88C5E943-3E9F-4E19-884B-C240CAB4BA05</gtr:id><gtr:impact>The PROUD trial results release in February 2015 received extensive coverage. Selected articles are below:

RADIO
Prof. Sheena McCormack (BBC5live breakfast 26 minutes in) http://www.bbc.co.uk/programmes/b0536kw9 
PROUD trial participant interview http://www.bbc.co.uk/programmes/p02ksq13 
Prof. Sheena McCormack, Dr. Mitzy Gafos and a trial participant (BBC5live 1:37 hours in) http://www.bbc.co.uk/programmes/b0536kwf#auto 
Dr. Mitzy Gafos (BBC radio4 today programme) http://www.bbc.co.uk/programmes/p02ks961
Dr. Mike Brady +Edwin Bernard, HIV Justice network (LBC Sheila Fogarty) http://chirb.it/s7krdg
Dr. Mitzy Gafos - BBC world service 7.50am
Dr. Amanda Clarke - BBC radio Sussex
Prof. Sheena McCormack http://www.newstalk.com/player/shows/Moncrieff/80813/the_game_changing_drug_which_prevents_hiv


TV
Dr. Mike Brady + ppt (Rob Shepherd) http://news.sky.com/story/1433828/hiv-drug-game-changer-hopes-for-gay-men
Dr. Richard Gilson - BBC4 news at 7pm
Dr. Mitzy Gafos - Sky news live 3.30pm, BBC news 9.30am

ONLINE/PRINT 
http://www.bbc.co.uk/news/health-31622337
http://www.bhiva.org/BHIVA-calls-for-rapid-assessment-of-PrEP-funding.aspx
http://www.europeanpharmaceuticalreview.com/29661/news/industry-news/proud-study-shows-pre-exposure-prophylaxis-is-highly-protective-against-hiv-infection/
http://www.aidsmap.com/Pre-exposure-prophylaxis-PrEP-stops-86-of-HIV-infections-in-PROUD-study/page/2947319/
http://news.sky.com/story/1433828/hiv-drug-game-changer-hopes-for-gay-men
http://www.avac.org/press-release/avac-calls-rapid-response-new-arv-based-hiv-prevention-data
http://www.cityam.com/210243/how-stop-spread-hiv-scientists-may-have-solved-problem-truvada
http://www.heraldscotland.com/news/health/preventative-hiv-drug-effective.119254681
http://www.independent.co.uk/life-style/health-and-families/health-news/hiv-pill-scientists-hail-discovery-of-gamechanger-that-cuts-the-risk-of-infection-among-gay-men-by-86-10068091.html#
http://www.itv.com/news/2015-02-25/drug-cuts-hiv-risk-by-87/
http://www.nhs.uk/news/2015/02February/Pages/Game-changer-HIV-drug-cuts-infection-risk-by-86-per-cent.aspx
http://www.nhs.uk/news/2015/02February/Pages/Game-changer-HIV-drug-cuts-infection-risk-by-86-per-cent.aspx
http://www.nzherald.co.nz/lifestyle/news/article.cfm?c_id=6&amp;amp;objectid=11408338
http://www.pinknews.co.uk/2015/02/24/proud-study-finds-prep-reduces-risk-of-hiv-infection-by-86/
http://www.reuters.com/article/2015/02/24/us-health-aids-prep-idUSKBN0LS2EV20150224
http://www.theguardian.com/society/2015/feb/24/daily-pill-truvada-cuts-spread-of-hiv-by-86-study-shows
http://www.ucl.ac.uk/news/news-articles/0215/250215-PROUD-pre-exposure-prophylaxis-protects-against-HIV
http://www.ucl.ac.uk/news/news-articles/0215/250215-PROUD-pre-exposure-prophylaxis-protects-against-HIV
http://www.who.int/hiv/mediacentre/news/croi2015-arvnews/en/</gtr:impact><gtr:outcomeId>56dc6b65a0c699.70523514</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Sarah Joseph invited to give a special lecture to third year medical studies on HIV vaccines at Kings College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5AD3DEE6-1115-4C4A-BDB9-2B7BE2E3D2CD</gtr:id><gtr:impact>Talk sparked interest and discussion about HIV vaccines among students.

-</gtr:impact><gtr:outcomeId>5464af4cb8db94.76929784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>15th European AIDS Conference (EACS), Barcelona, 22-23 Oct. 2015. Prof. Sheena McCormack plenary presentation 'PrEP - from Science to Implementation'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>376D0DAC-47AC-4633-BD37-B5FA3D752146</gtr:id><gtr:impact>An opportunity to place PrEP in the context as there have been so many clinical trials in diverse populations, the majority of which demonstrate effectiveness. The evidence for efficacy is clear, and two European trials in gay men demonstrate the potential to dramatically influence the epidemic in Europe.

A call to action for clinicians and community to lobby European governments to implement PrEP as a matter of urgency for key populations at risk of catching HIV.

xxx</gtr:impact><gtr:outcomeId>5666fa5f3fdf75.62336962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Daily Mail article: 'Wonder drug' which can reduce HIV risk by 92% could be offered on the NHS, published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7587A3A1-B8FC-42C6-8C51-E0C13591A3FA</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463faa10d3c91.04919217</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/health/article-2796900/wonder-drug-reduce-hiv-risk-92-offered-nhs-landmark-trial-sped-up.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CROI presentation by Prof. Sheena McCormack of PROUD results 24.02.15</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98F4580C-FAC6-416B-BC56-15E740F656F8</gtr:id><gtr:impact>CROI presentation of PROUD results 24.02.15 in a session that included the IPERGAY trial results too - two European randomised trials of Truvada as PrEP, conducted in gay men, both showing an 86% reduction in HIV acquisition. They were heralded as the most important results of the conference, and likened to the 1996 conference when triple therapy was shown to effectively control viral replication in people living with HIV.</gtr:impact><gtr:outcomeId>56bc997d89f5f2.18776522</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. McCormack participation in a Press meeting 24.02.15 during the CROI conference on PROUD trial results</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C5EA9C9E-6877-4641-A3FA-99652A96AF63</gtr:id><gtr:impact>Invited to the Press meeting at CROI 24.02.15 following presentation of the PROUD results. The media was excited about the two European trials that both reported a 86% reduction in HIV (the largest reported to date), and asked why European governments were not responding to these impressive results.</gtr:impact><gtr:outcomeId>56bc9b462aa747.81219264</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Controlling the HIV Epidemic with Antiretrovirals: Having the Courage of our Convictions' (Paris, 1st October 2015). Prof. Sheena McCormack panel speaker: 'Early PrEP implementation: perspectives from the field' session</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>31689F0A-8FD5-439F-8072-27826044D79D</gtr:id><gtr:impact>Brief talks followed by a debate. The Chief Investigators of PROUD and IPERGAY were advocating for more activism in Europe to draw government attention to the rising HIV incidence in key populations and the need to implement PrEP.

xxx</gtr:impact><gtr:outcomeId>5666f5dee31e19.26745924</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Help Make History website www.helpmakehistory.mrc.ac.uk to increase interest in public participation in vaccine trials/information sharing</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5782AFED-8F1C-4DB1-90FA-EA203A376BC4</gtr:id><gtr:impact>Increase in number of registrants to Help Make History database of potential participants to vaccine trials. Increase in number of direct enquiries relating to participation in vaccine trials.

Registration to the Help Make History database of potential participants to vaccine trials has increased, along with the number of direct enquiries. Cuthivac 001 trial is now fully enrolled (as of 6th Nov 2014) as as direct result of this engagement, along with profiling of vaccine recruitment on social media.</gtr:impact><gtr:outcomeId>545cbbb70d0884.85862836</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.helpmakehistory.mrc.ac.uk</gtr:url><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participation in Community seminar 'Community Conversation on understanding new HIV prevention data and what it all means'; took place during CROI Conference, 25th  Feb 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E29B31E3-F64C-4D39-A79B-DD315B5BE285</gtr:id><gtr:impact>Participation in Community seminar 'Community Conversation on understanding new HIV prevention data and what it all means' ; took place during the CROI Conference, 25th Feb 2015. The two European trials had caused excitement amongst community organisation, tempered by the lack of benefit seen in the vaginal gel trial conducted in South Africa.</gtr:impact><gtr:outcomeId>56bc9aa6ab5766.66678903</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ADPH (Association of Directors of Public Health) / PHE Sexual Workshop, St. Bride's Foundation, Fleet Street, 5th October 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>16B80F89-2837-4449-8C04-01A6A889499D</gtr:id><gtr:impact>The Directors of Public Health and other members of the audience are responsible for oversight of commissioning of sexual health and family planning services. This was an opportunity to promote PrEP and the potential impact this could have on the HIV epidemic. One public health expert from Jersey told me that she would implement a PrEP service on return for individuals travelling to high prevalence countries for holiday or work.

xxx</gtr:impact><gtr:outcomeId>5666f9382bf618.33591708</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Sheena McCormack featured on BBC2 TV for The Victoria Derbyshire programme, discussing the 'Chemsex' scene, 2nd July 2015.</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A91E7F88-9747-4BFF-B8A4-3E099DB07C09</gtr:id><gtr:impact>Prof. Sheena McCormack provided content for BBC2 TV programme 'Chemsex' which aired 2nd July 2015.
Watch it at http://www.bbc.co.uk/iplayer/episode/b060pr3k/victoria-derbyshire-02072015 

Also featured on BBC Radio 4; an article for BBC Online, Attitude and Gay Time.
Was 'Pick of the Day' in the Telegraph and the Evening Standard featured. Previewed in the Radio Times and the story was featured on 'Today', Radio 4.</gtr:impact><gtr:outcomeId>56bcdfdbb47752.83262688</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Independent article: NHS to offer tablet which can reduce HIV risk by 90%; published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6583F89F-FCE8-4C7F-A54C-993CC97CE9B8</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f9d4b5d418.52786427</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.independent.co.uk/life-style/health-and-families/health-news/nhs-to-offer-tablet-which-can-reduce-hiv-risk-by-90-9799965.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Engagement of PROUD trial participants / sharing of information through trial the PROUD trial website www.proud.mrc.ac.uk</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3D3D8249-ECC2-41ED-B0F1-2EDE6E082C98</gtr:id><gtr:impact>We engage with study participants, the media, academics and anyone interested in PrEP/HIV research through the study website which we regularly update.

Increase in enquiries relating to the PROUD trial.</gtr:impact><gtr:outcomeId>545cba27405fa4.79365559</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk</gtr:url><gtr:year>2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD study update presentation to the UK CAB (MG)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>598CC498-6950-4F43-9787-B8FBFB06D8C6</gtr:id><gtr:impact>My presentation was one of four presentations about PrEP. The sessions generated discussion about future access to PrEP. A number of the CAB members are also members of the Clinical Reference Group (CRG) who will be involved with the review of PrEP in the future.

The group identified a series of questions that they intended to present to Gilead including the cost of Truvada and licensing of Truvada at the EMA.</gtr:impact><gtr:outcomeId>54c64387c32ee0.45924940</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ukcab.net/meetings/next-meeting/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Letter to The Times newspaper editor on PrEP</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CCF5AE6B-4738-4CBE-9F24-F6CAE15D49AE</gtr:id><gtr:impact>Letter to The Times, Editor: 
Written as below:

Dear Sir,

A drug now exists that prevents HIV: pre-exposure prophylaxis (PrEP). When taken correctly, it is near 100% effective. But NHS England is standing in the way of utilising this remarkable breakthrough to tackle the HIV epidemic.

After 18 months of delays and false starts, David Cameron has now committed NHS England to giving an answer on PrEP imminently.

As the decision looms, arguments against PrEP are running out of steam. Men accessing the drug in trials haven't shown an increase in STIs. The NHS spends 50 times more on HIV treatment than prevention.

PrEP, alongside condom use, has enormous potential to reduce HIV transmission. It is available in the US, France and Kenya and soon in Australia. The Government must now make PrEP available to people at high risk in England. Every day this is delayed, at least seven people will be infected with HIV.

We anticipate a long overdue answer on 31st May, when NHS England will decide if PrEP should be considered for funding. This could be a critical turning point in the fight against HIV - it must not pass us by.

Yours sincerely,

Deborah Gold, Chief Executive, National AIDS Trust Ian Green, Chief Executive, Terrence Higgins Trust Professor Sheena McCormack, PROUD trial Chief Investigator Dr Elizabeth Carlin, President, British Association for Sexual Health and HIV Dr David Asboe, Chair, British HIV Association Matthew Hodson, Chief Executive, GMFA - the gay men's health charity Marion Wadibia, Chief Executive, NAZ Tom Doyle, Chief Executive, Yorkshire MESMAC Rob Cookson, Deputy Chief Executive, LGBT Foundation Allan Anderson, Chief Executive, Positively UK Gus Cairns, European AIDS Treatment Group Monty Moncrieff, Chief Executive, London Friend Mark A. Santos, Director, Positive East Caspar Thomson, Executive Director, NAM Dr Greg Ussher, Chief Executive, METRO Ben Collins, ReShape Dr Will Nutland and Marc Thompson co-founders PrEPster Greg Owen and Alex Craddock, co-founders, iwantprepnow.co.uk Michelle Ross, co-Founder cliniQ Silvia Petretti, Memory Sachikonye and Paul Clift, UK Community Advisory Board Sophie Strachen, Trustee, Sophia Forum Dan Glass, ACT UP LONDON (AIDS Coalition To Unleash Power) Simon Collins, Director, HIV i-Base Robert Fieldhouse, Editor, BASELINE Magazine Lisa Power, MBE</gtr:impact><gtr:outcomeId>5798cd685b2b54.45708809</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mentoring of British Commonwealth Fellow (Ugandan statistician)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2D75244-28C8-455D-BB8D-96C3CA6D015C</gtr:id><gtr:impact>A British Commonwealth Fellow attended some mentoring at our Unit, including attending a TaMoVac trial management teleconference in 2015. The mentee asked lots of questions about how we ran trials and we equally learnt from her about perceptions of HIV treatment/prevention in Uganda. Dr. Sue Fleck talked to her about Trial Management issues in HIV Prevention trials.

The mentee attended various sessions at CTU and would take her learning back to her workplace.</gtr:impact><gtr:outcomeId>56670f76402237.80327232</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article on www.RT.com: HIV drug cutting transition risk 90% may be offered on NHS; published 17th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4F3B80C6-B5FE-4876-8B17-430BFE1C974D</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463fd0f848545.08307994</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://rt.com/uk/196816-drug-reduce-hiv-nhs/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Moncrieff show, Ireland. Prof. Sheena McCormack interviewed on PrEP research, 5th March 2015</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C587FEDF-E780-4EAE-A2A6-DD9D7B6191FF</gtr:id><gtr:impact>Q&amp;amp;A on popular Irish radio show on PrEP and the results of PROUD in particular.</gtr:impact><gtr:outcomeId>56da39fcaacff2.73546373</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European AIDS Treatment Group (EATG), Brussels meeting 23-25 Jan 2015 to bring treatment advocates up to speed on HIV prevention topics. Prof. Sheena McCormack presented PrEP.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1C072086-F4CB-4610-91C4-648CE8F4A0FC</gtr:id><gtr:impact>At this point in time the treatment activist community was aware that there were two European trials with results that had led them to change much earlier than expected to offer participants at risk of HIV active treatment (Truvada as PrEP).

At this meeting there was an opportunity to explain why the two trials, PROUD and IPERGAY were designed so differently, and to describe the baseline characteristics. PROUD was an open-label design in which participants were randomised to receive PrEP immediately or after 12 months follow-up. The regimen offered was daily Truavda. IPERGAY was placebo-controlled, and the regimen was double dose before sex, and daily through to 2 doses after sex.</gtr:impact><gtr:outcomeId>56da372d0d4ce3.60258973</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKHVC spoke003 results presentation to participants, at CTU, 13th July 2015 evening</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8797221B-2A19-4E22-BBA0-442575963713</gtr:id><gtr:impact>UKHVC spoke003 results presentation to participants, at CTU, 13th July 2015 evening</gtr:impact><gtr:outcomeId>56bce0ff5df8a1.12102308</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos presented An Update on PROUD to the European AIDS Treatment Group (EATG) Webinar 2: PrEP on 24-11-2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>04643944-FEEF-422A-AD6A-AA4E796478D7</gtr:id><gtr:impact>Initiated discussion about PrEP in Europe

Linkage with European advocates</gtr:impact><gtr:outcomeId>546f0ad54184f4.19919937</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.avac.org/event/eatg-webinar-2-pre-exposure-prophylaxis</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PrEP Twitter Q&amp;A, World AIDS Day 1st December 2015. Participation by Prof. Sheena McCormack</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B957893F-8410-490D-B91D-7B6B434B3269</gtr:id><gtr:impact>As well as the questions that spontaneously arrived, there were questions already prepared designed to raise awareness. The Chief Investigator, a member of the Community Engagement Group and a PROUD participant took part in #PROUDQandA</gtr:impact><gtr:outcomeId>56dc4e8b61c275.41094840</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://storify.com/MRCCTU/world-aids-day-q-a-prep-and-the-proud-study</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Weekly departmental academic meeting, Courtyard Clinic, St. George's Hospital, Sexual Health &amp; HIV dept. Prof. Sheena McCormack talk on PrEP/PROUD (London, 19th August 2015)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>364DAB09-02DD-4E34-83B0-9C736BA8DF96</gtr:id><gtr:impact>An opportunity to promote PrEP to an audience that was familiar with the science but not yet acting on it. Practitioners were encouraged to speak to attendees at the sexual health clinic about PrEP in order to have a more informative discussion about sex, and risks to determine whether PrEP would be a useful addition for each individual.

XXX</gtr:impact><gtr:outcomeId>5667079dedb675.98626278</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PrEP and PROUD plenary at18th Annual BASHH Conference for SAS Doctors Working in Sexual Health. Warwick University, 5th Sept. 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC81F120-1AE5-49DB-8D3B-D6EA8B6F9EA0</gtr:id><gtr:impact>An opportunity to reach a broader audience of practitioners working in sexual health, some of whom had not heard of PrEP before and very few of whom were overseeing PrEP or even aware of the PROUD study.

xxx</gtr:impact><gtr:outcomeId>5666ed72eb6523.71496795</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview for Dirtyboyz for article July 2014 issue (pp. 54-55)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A4FD375-BCF6-4B67-84D1-9E691C0D26E9</gtr:id><gtr:impact>Interview with journalist.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e9930e9b50.22493859</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. Sheena McCormack presented at Terrence Higgins Trust meeting, Royal College of Physicians, London, 22nd June 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4A733EE6-39F7-46BA-9DD7-71136F7C1FFC</gtr:id><gtr:impact>THT talk, Royal College of Physicians, London, 22nd June 2015 focused on PrEP and placing it in context with other interventions to prevent HIV, and providing a vision of the impact PrEP could have on the epidemic.</gtr:impact><gtr:outcomeId>56bcd052bbe0e5.48829862</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof. McCormack attendance at MTN Phase 3 Rectal Microbicide Design meeting, Washington DC, 18-19.02.15</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3942D241-6F77-4F5C-B077-3BA0C911D22C</gtr:id><gtr:impact>A workshop to review the available data on tenofovir rectal gel and the options for the final stage of evaluation, one of which is the immediate deferred design used to demonstrate the effectiveness of daily oral Truvada in PROUD.</gtr:impact><gtr:outcomeId>56bc9bdf058f30.21105662</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prepster event at The Eagle, London on 19th March 2016. Showing of PROUD film and panel discussion of PrEP experts</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3AD4326B-B3C9-47E1-A4BE-EEC87B5E6E26</gtr:id><gtr:impact>Over a hundred and fifty people turned up for the Prepster event at The Eagle London on 19th March 2016.

The evening was hosted by Prepster co-founder Will Nutland and started with a showing of Nicholas Feustel's short film about the PROUD PrEP trial https://vimeo.com/132412294 followed by a panel discussion of PrEP experts including;
?Nicholas Feustel - film maker Georgetown Media and PrEP activist
?Marc Thompson - PrEPster co-founder and Peer Mentor at Positively UK
?Sheena McCormack - PROUD study + Dean Street
?Mike Brady - Medical Director, Terrence Higgins Trust
?Greg Owen - I Want PrEP Now</gtr:impact><gtr:outcomeId>5790a75c30b377.80963506</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://vimeo.com/132412294</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article AIDSMap/NAM: PROUD UK PrEP study completes enrolment - first data give participants' background and risk factors, published 9th April 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>067FD7B9-8C62-4852-AAD8-CD0671A19835</gtr:id><gtr:impact>Article by PROUD Community Engagement Group member/TSC Co-Chair.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463e5b6bedc24.17010734</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/page/2845218/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary presentation 'The madness of HIV prevention trials'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9C53F1B4-04F4-43AE-98E1-B9F072B3B172</gtr:id><gtr:impact>The talk highlighted the challenges encountered in the conduct of HIV prevention trials. The answer can be disappointing because these issues were not overcome, or because the product did not work.

xxx</gtr:impact><gtr:outcomeId>5666fe2eadfc13.37704142</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article for AIDSMap/NAM: High effectiveness seen in English PrEP trial; published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EC46B10A-C539-4BF3-A63F-AC22C6221428</gtr:id><gtr:impact>Article produced by Gus Cairns (co-chair of the PROUD Trial Steering Committee)/Community Engagement Group member.

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f914162b59.46665632</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.aidsmap.com/High-effectiveness-seen-in-English-PrEP-trial/page/2912952/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ReShape General Meeting (London, 9th Nov. 2015)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>647B0C4E-FFE3-4592-9890-C622E4C220DF</gtr:id><gtr:impact>This group was initiated by an activist from the AIDS treatment era of the 1980s and 1990s to bring third sector individuals and others interested in supporting a more active approach to lobbying for better access to treatment and prevention services in the UK. These services are threatened by the fragmentation that the 2013 Health and Social Welfare Act has caused by shifting responsibility for sexual health to Local Authorities, thereby separating HIV and STI prevention and treatment from HIV care.

xxx</gtr:impact><gtr:outcomeId>5666fd7c97aa63.70229846</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CUTHIVAC 001 trial participants meeting, St. Mary's hospital, London 15th Feb 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DD01DCA8-0F48-4643-9464-B3445A791AC9</gtr:id><gtr:impact>Presentation of the results to the healthy volunteer participants on this HIV vaccine trial.</gtr:impact><gtr:outcomeId>56dc53787972a3.67958667</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - article for HIV I-Base: UK PROUD study to provide PrEP earlier than expected: planned follow-up in this HIV prevention study to continue for two years; article published 16th Oct 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CB1A2D48-664B-4839-99C3-B2ED3E4E0B64</gtr:id><gtr:impact>Article written by independent member of the PROUD IDMC (Simon Collins).

Media dissemination of information about PrEP/PROUD.</gtr:impact><gtr:outcomeId>5463f84df31202.29985967</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://i-base.info/uk-proud-study-to-provide-prep-earlier-than-expected/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mitzy Gafos presented on &quot;PrEP- is the time right?&quot; Update on the PROUD study to the Wessex BASHH Regional Clinical Network Group Meeting 19-11-2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>16B692E6-FDD0-4FB4-BA47-691A648D3EE0</gtr:id><gtr:impact>The presentation generated a discussion about PrEP roll out in the UK - providers wanted more information about cost effectiveness, toxicity, resistance and targeting of PrEP in the NHS (15 doctors and health advisers present)

The presentation will be shared around the group</gtr:impact><gtr:outcomeId>546f0997440640.40645074</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media - Interview  with The Times for article: Trial of pill to prevent HIV could lead to rise in promiscuity, scientists admit; published 8th Feb 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>89508D54-AEA8-4F96-9858-8D26CCFB8F8D</gtr:id><gtr:impact>Interview with journalist

Media dissemination of information about PrEP/PROUD</gtr:impact><gtr:outcomeId>54639e1cce4403.48180941</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.thetimes.co.uk/tto/health/news/article4000861.ece</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prepster http://prepster.info/ and the LGBT Foundation, Manchester organised a showing of Nicholas Feustel's short film on the PROUD PrEP trial followed by a discussion with a panel of PrEP experts.</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>49626330-1C02-40C8-8E28-7B8D305D1E20</gtr:id><gtr:impact>Prepster http://prepster.info/ and the LGBT Foundation organised an evening showing in Manchester of Nicholas Feustel's short film on the PROUD PrEP trial followed by a discussion with a panel of PrEP experts.

Dr. Will Nutland (Prepster) hosted a panel of:

Yusef Azad, Director of Strategy - National AIDS Trust
Rob Cookson, Deputy Chief Executive - LGBT Foundation
Alex Craddock, Co-Founder - I Want PrEP Now
Sheena McCormack - PROUD Study + Dean St London
Chris Ward, Consultant Locum - The Hathersage Centre</gtr:impact><gtr:outcomeId>5790cfecc964a7.20338488</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://vimeo.com/132412294</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Network for Multidisciplinary Studies on ARV-Based HIV Prevention (NEMUS). Prof. Sheena McCormack participated in webinar presented by Prof. Jean-Michel Molina: PrEP in MSM: How data from Ipergay fit in the context, 28th April 2015</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>67DB3F07-03ED-4226-A3FF-8D8B23CF6174</gtr:id><gtr:impact>The Network for Multidisciplinary Studies on ARV-Based HIV Prevention (NEMUS) run educational webinars to update professionals and community organisations regarding the latest research. Sheena McCormack who was Chief Investigator on the PROUD study participated as an expert in the discussion that followed a presentation by Prof. Jean-Michel Molina: PrEP in MSM: How data from IPERGAY fit in the context.</gtr:impact><gtr:outcomeId>56bca396e27b74.22851294</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PrEP and PROUD talk to Gilead Sciences, Holborn, London, 13th May 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A65911E2-09E8-47AD-A2BB-2E7FB3563769</gtr:id><gtr:impact>Talk on PrEP focusing on the two recently reported European trials - PROUD and IPERGAY. The discussion included how negotiations between Gilead (who have a monopoly on the market for PrEP and hepatitis C treatment, both of which are highly effective and both grossly over-charged) and governments in the interests of public health.</gtr:impact><gtr:outcomeId>56bcb2870207c0.57325079</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PROUD documentary and Voices of Participants premiere 1st July 2015, The Cinema Museum, SE11, London</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78680A78-5FAA-4777-80C0-568DC676B28F</gtr:id><gtr:impact>PROUD documentary and Voices of Participants premiere, The Cinema Museum, SE11, London. Launched 1st July 2015.

Further screenings around the UK have taken place during 2015 and also a German-language screening as part of Hamburg Gay Pride 28th August 2015. See http://www.proud.mrc.ac.uk/films for more information.

The screenings have been well attended and well received, with numerous requests for further information following each event.</gtr:impact><gtr:outcomeId>56be1bc46886a0.56619456</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.proud.mrc.ac.uk/films</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>491380</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical trial Collaboration - UKHVC</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>083844</gtr:fundingRef><gtr:id>D27DD542-95F9-4722-BA9B-F92044DA8EB9</gtr:id><gtr:outcomeId>EfVL69aoBSD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>324810</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CUTHIVAC (European Commission Collaborative Project - Large Scale Integrating Project)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>241904</gtr:fundingRef><gtr:id>F40E3320-9765-4585-9DF6-3C58915EEAD0</gtr:id><gtr:outcomeId>s7zYYS9aT8Q0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9279</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HOME PEPSE: 'The role of home packs of HIV post-exposure prophylaxis for sexual exposure to improve the speed and appropriate uptake of PEPSE in high risk individuals' (Guy's and St. Thomas's NHS Foundation Trust)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>St Thomas' Hospital</gtr:fundingOrg><gtr:id>0FFC8CAC-2276-4670-9159-E2D0A6F4787A</gtr:id><gtr:outcomeId>56df37f5811854.93656388</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>TRANSVAC</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>TNA1204-5 - HIV_vaccine_breakthrough</gtr:fundingRef><gtr:id>5CB4B7A4-12BC-4AEF-8B8C-49CB810A5855</gtr:id><gtr:outcomeId>GE2MJ77R148</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4851440</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PROUD trial: Medical Research Council Clinical Trials Unit Core funds, Gilead Sciences Inc., Health Protection Agency (HPA) / Public Health England (PHE)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>-</gtr:fundingRef><gtr:id>563CF223-F384-449A-8C44-69C631289E0B</gtr:id><gtr:outcomeId>QFWxXwhU9az</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450651</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Clinical Trial/Capacity Building - Tamovac II</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>IP.07.33112.001</gtr:fundingRef><gtr:id>7379445B-0B69-4286-B10E-1FAD31E7D828</gtr:id><gtr:outcomeId>omSoJ6Txhrw0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>287804</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PANTHEON - A comprehensive assessment of the cost effectiveness of HIV prevention and testing strategies, including HIV self-testing, among men who have sex with men (MSM) in the UK. (NIHR Programme Development grant)</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>RP-PG-1212-20006</gtr:fundingRef><gtr:id>857D54B5-9560-4162-A0A0-DCCB68D80F63</gtr:id><gtr:outcomeId>56df13e964b0c5.79335530</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66415</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKHIV Vaccine Consortium spoke 003 trial: MRC DCS scheme</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E16454EB-4374-4FC4-BE0C-96B39D9768ED</gtr:id><gtr:outcomeId>tf2HSkrw4tY</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European PrEP Group</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>B9CDE427-FD5E-4107-BBB1-C27AA73BBB21</gtr:id><gtr:impact>This group was initiated and is coordinated by Sheena McCormack to provide a forum for exchange of knowledge and sharing tools (surveys, data collection forms, protocols etc) in order to accelerate research into pre-exposure prophylaxis (PrEP) in Europe. Although there have been multiple clinical trials assessing PrEP, none of these were conducted in European populations prior to 2012 when iPerGay and PROUD launched in France and the UK.</gtr:impact><gtr:outcomeId>546392894a5c53.30289613</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chelsea &amp;amp; Westminster Directorate teaching session, 15th July 2015 PROUD and PrEP in clinic</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>C31F1FA1-0646-4BBF-9B3F-FA648DE7B3B2</gtr:id><gtr:impact>Chelsea and Westminster Hospital (CWH) Directorate teaching session, 15th July 2015
The CWH clinics see a large number of HIV negative men who have sex with men, and were a key partner in the PROUD study recruiting more than 1 in 5 of the study participants. The results of the PROUD study revealed a sub-population of MSM with particularly high HIV incidence, in whom PrEP was extremely effective. Ever since the results were reported in February 2015 MSM have been coming into clinics requesting PrEP.

Following my talk, the Dean Street team decided to launch a PrEP clinic to see what the demand was. This started in September 2015 and has been fully booked since launch.</gtr:impact><gtr:outcomeId>56bce691410cc5.00076297</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Minister for Public Health visited 56 Dean Street, 16th July 2015</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9E645674-C5D2-4CE4-9C60-350CE12F9C9C</gtr:id><gtr:impact>Minister of Public Health for England and Wales visited 56 Dean Street and Dean Street Express to see how efficient the screening service is now that it is automated with the largest CEPHEID machine in Europe in situ in the Express, 16th July 2015. Opportunity to explain that behaviour takes a long time to change, but in the meantime we can reduce the time from diagnosis to treatment, and PrEP can reduce the risk of HIV whilst people are in a period of risk.</gtr:impact><gtr:outcomeId>56bce7622bc121.74645647</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.chelwest.nhs.uk/services/hiv-sexual-health/clinics/dean-street-express</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PROUD Briefing paper Pre-exposure Prophylaxis to prevent HIV among MSM in the UK, Sept 2015</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3D3AAC48-98F3-4F9D-A531-BC3D13EA6829</gtr:id><gtr:impact>PROUD was a game changer for PrEP for two reasons. Firstly Truvada was more effective at preventing HIV in this open-label trial than in previously reported placebo-controlled trials, and secondly the trial schedule mirrored routine practice with quarterly visits, whereas previous trials had followed a monthly schedule. The study was conducted in men who have sex with men attending sexual health clinics in England. Policy work is ongoing towards an NHS decision in June 2016.</gtr:impact><gtr:outcomeId>56dc61fb1d05c4.71831735</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/97173/97177/proud_results_policy_brief_final</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Regulatory meeting, Paris, 25-26 Jan 2015</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3657842-7E75-4FC0-9F28-29361BE9D81E</gtr:id><gtr:impact>Under pressure from French activists, Gilead had submitted an application to use Truvada as PrEP on a named patient basis in 2013. ANSM, the French Regulatory Authority, was considering this and was aware that there were two European trials, IPERGAY (France) and PROUD (UK) that were about to report at a forthcoming conference (February 2015).

ANSM requested that I attend in my role as Chief Investigator of PROUD, to present the study design and the baseline characteristics, in order to prepare them to better understand the result.</gtr:impact><gtr:outcomeId>56da37ccd388d6.04586170</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ADPH (Association of Directors of Public Health) / PHE Sexual Workshop, St. Bride's Foundation, Fleet Street, 5th October 2015, attended by Prof. Sheena McCormack</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>11BDBF07-85D6-4EA3-B3BC-9491FB87242A</gtr:id><gtr:impact>PROUD was particularly relevant to this audience of public health experts who will influence the implementation in the event that the NHS approves PrEP. PROUD and IPERGAY were two trials conducted in men who have sex in men, in UK and France respectively. Both showed that Truvada was extremely effective at preventing HIV, whether given daily or before and after sex, and both had very high rates of HIV in the control group - much higher than expected based on surveillance data. The trials reported in 2015, and caused tremendous excitement amongst the clinical community and MSM. 

Disseminating these results to Directors of Public Health was crucial to preparing them for a national PrEP programme.</gtr:impact><gtr:outcomeId>5666f67a65abe3.33233030</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Statistics/Data Management training course for staff working on Tamovac II, Dar es Salaam, Tanzania 24-28 Nov. 2014</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>17A15770-029F-4DDA-8783-0A796D1884CB</gtr:id><gtr:impact>The training was given by Dr Claire Cook (Data Scientist) and Dr. Adrian Cook (Statistician) of MRC CTU at UCL. This was a capacity building exercise planned for data management staff within the Tamovac II EDCTP network and took place in Dar es Salaam (1 week duration). Staff attended from sites in Mozambique and Dar.

Other one to one mentoring in Statistics and remote training by webex from MRC CTU at UCL staff through the 'Statistics for non-Statisticians' course was also been given during the duration of the Tamovac II grant which had been of benefit to the ongoing development of staff. The training was well received by all who attended. The MRC CTU at UCL Tamovac II budget also funded 'Open Clinica' data management training at 2 sites in Tanzania.</gtr:impact><gtr:outcomeId>56d9db274964f5.34981492</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>European AIDS Clinical Society (EACS) guidelines v8 presented at Barcelona, 22-23 Oct. 2015.</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E4122FF0-0ED1-4A75-BBB7-F1B7C8145340</gtr:id><gtr:impact>Version 8 of the clinical guidelines contained guidance on pre-exposure prophylaxis for the first time. Professors Molina and McCormack were invited to join the committee to draft this section.</gtr:impact><gtr:outcomeId>5666fcc33af486.55660240</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Update to PrEP Position Statement on BHIVA website (14th Sept. 2015)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C0D1A35B-27FB-4AF4-B858-C03705AAE5E5</gtr:id><gtr:impact>The update to the Position Statement provided more detail for practitioners who are trying to advise and monitor people who have purchased their own drug to use as PrEP.</gtr:impact><gtr:outcomeId>5666f009e95e43.25131271</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>https://www.bhiva.org/documents/Publications/PrEP_BHIVA_BASHH_Update_14September15_Final.pdf</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Presentation on PROUD at BASHH / PHE Ordinary General Meeting (OGM), 13th March 2015 (David Dolling)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA0822F8-A560-4C0B-BFF4-4EBDAA097F71</gtr:id><gtr:impact>This was the first national presentation following the public release of the results of the PROUD study at an international conference the month before.

The results had a considerable impact on practitioners for two reasons. Firstly the rate of HIV was much higher than expected based on routine clinic data, demonstrating that the men who came forward to take part were exactly who we should be giving PrEP to. Secondly, PrEP proved extremely effective at preventing HIV, in spite of high levels of other sexually transmitted infections which the clinical community suspected would undermine the biological efficacy.</gtr:impact><gtr:outcomeId>56da3a8f04db05.97853126</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PROUD trial citation in WHO PrEP Implementation guidelines, 2015</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>WHO PrEP Implementation guidelines (draft)</gtr:guidelineTitle><gtr:id>79B11ABD-82D8-4BF3-88D9-9E292FB0B89B</gtr:id><gtr:impact>PROUD was a game changer for PrEP for two reasons. Firstly Truvada was more effective at preventing HIV in this open-label trial than in previously reported placebo-controlled trials, and secondly the trial schedule mirrored routine practice with quarterly visits, whereas previous trials had followed a monthly schedule. The study was conducted in men who have sex with men attending sexual health clinics in England.</gtr:impact><gtr:outcomeId>56dc613041eb02.51225637</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/97173/97177/report_on_public_involvement_meetings_with_prep_users_enrolled_PROUD_trans_service_users_cliniQ_who_prep_implementation_guidelines</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Weekly departmental academic meeting, Courtyard Clinic, St. George's Hospital Teaching session, 19th August 2015 PrEP and PROUD</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>91230444-9095-433C-BEE3-393EC9F4D99D</gtr:id><gtr:impact>St George's were not a partner in the PROUD study, but they do see HIV negative men who have sex with men who are at risk and who would benefit from PrEP. The results of the PROUD study revealed a sub-population of MSM with particularly high HIV incidence, in whom PrEP was extremely effective. Ever since the results were reported in February 2015 MSM have been coming into clinics requesting PrEP.</gtr:impact><gtr:outcomeId>566707600baf29.33830410</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Full title: 'A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultiHIV DNA immunisations administered via the Intramuscular, Intradermal and Transcutanous routes in healthy male and female volunteers.

Trial participants: 30 male and female volunteers aged 18-45 years old who are at low risk of HIV infection.

Funding provided through the European Commission CUTHIVAC grant.</gtr:description><gtr:id>4571A2E3-2EEB-4BCD-B41D-E16DAD9F332F</gtr:id><gtr:impact>Participants meeting took place January 2016.
Analysis ongoing.</gtr:impact><gtr:outcomeId>56defb873a1f25.69463297</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CutHIVac 001 trial</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14858</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>PROUD is designed to address an unique question regarding Truvada-PrEP, namely the effectiveness when people know they are on a drug that reduces HIV, as this may lead people to increase their risk and as a consequence expose themselves to more HIV and sexually transmitted infections (STI). Gay men are randomised to have access to daily oral Truvada at enrolment or after one year of follow-up, and all participants have access to the standard prevention package throughout.

Truvada as PrEP has been licensed as PrEP in the USA and this is a pilot study.

Funding provided through: MRC Clinical Trials Unit at UCL, Public Health England, and Gilead Sciences. 

544 study participants currently in active follow up.

The PROUD trial reported at the Conference for Retroviruses and Opportunistic Infections (CROI), February 2015 http://www.croiwebcasts.org/console/player/25539?mediaType=audio&amp;amp;</gtr:description><gtr:id>89A9D3A4-237F-4EF1-B5A6-AD80CAC44C37</gtr:id><gtr:impact>PROUD was a game changer for PrEP for two reasons. Firstly Truvada was more effective at preventing HIV in this open-label pilot phase than in previously reported placebo-controlled trials, and secondly the trial schedule mirrored routine practice with quarterly visits, whereas previous trials had followed a monthly schedule. The study was conducted in men who have sex with men (MSM) attending sexual health clinics in England. When PROUD announced the decision to offer PrEP to those whose access was deferred, IPERGAY asked their Data Monitoring Committee to advise them what to do in their placebo-controlled trial which was also being conducted in MSM, in France. It transpired that Truvada was equally effective when MSM were advised to take drug before and after sex. This caused tremendous excitement when the results were presented back to back at an international conference, and the excitement sparked enthusiasm across Europe.

In November 2015 the French regulatory authority approved the use of Truvada as PrEP on a named patient basis, and the French Minister of Health announced at the end of the same month that the costs of the drug would be fully reimbursed by the social security system. NHS England is about to issue a Commissioning Policy for public consultation.</gtr:impact><gtr:outcomeId>NdjYsZQiRyt</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Pre-exposure prophylaxis for HIV infection (PROUD trial)</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:url>http://www.proud.mrc.ac.uk</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Clade C DNA
Clade C MVA
Clade C rgp140
GLA</gtr:description><gtr:id>CDDF00B6-F908-4C80-A1C5-2FB6A5B1A5CD</gtr:id><gtr:impact>Completion of healthy volunteer HIV vaccine trial, evaluating products developed through the Wellcome Trust funded UK HVC.</gtr:impact><gtr:outcomeId>56ddcbbbc99cb0.38657098</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>UK HVC Spoke3</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14173</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Full title: 'A randomised phase I/II study to assess the safety and immunogenicity of the DNA-GTU vaccine administered by two novel methods compared to placebo in HIV-infected patients on antiretroviral therapy.'

Vaccine administered trancutaneously or through electroporation (enhanced intramuscular delivery).

Trial participants: 30 HIV infected male and female volunteers aged 18-45 years who have been on ART for at least 6 months with 2 or more HIV plasma viral load measurements; 50 copies HIV RNA/ml prior to enrolment.

Funding provided through the European Commission CUTHIVAC grant.</gtr:description><gtr:id>E7BCB4A4-59A3-4F83-959E-14E085FB3F50</gtr:id><gtr:impact>Analysis still to be done, trial fully recruited and participants in follow up.</gtr:impact><gtr:outcomeId>56defd650c25e0.48486784</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CutHIVTher trial</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://www.hra.nhs.uk/news/research-summaries/cuthivther-001/</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>DNA plasmid dervied from clade C CN54 which has been through Phase I and IIa trials. Significant benefit was gained from three primes (reported at CROI Feb10).</gtr:description><gtr:id>F2CA6B3C-60A6-45E9-94CC-B0B05F7A64CD</gtr:id><gtr:impact>Benefits of third DNA demonstrated in terms of broader and stronger immune responses.</gtr:impact><gtr:outcomeId>s7C5ySbmwPZ</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DNA HIV CN54 prime followed by NYVAC C boost</gtr:title><gtr:type>Preventative Intervention - Nutrition and Chemoprevention</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The database was developed by the MRC CTU at UCL team to allow study participants to remotely record sexual and adherence behaviour on daily diaries and monthly questionnaires.</gtr:description><gtr:id>19FB8949-FB4C-4511-A799-E473377E36A0</gtr:id><gtr:impact>The database has allowed real time data collection directly from study participants</gtr:impact><gtr:outcomeId>546236826aa658.92598906</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PROUD participant database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>HIV vaccine trial database</gtr:description><gtr:id>8E2A3A4C-281B-4E1D-9EE1-AFF6A1181A62</gtr:id><gtr:impact>Generation of reports for safety monitoring by the Trial Management Group and Independent Data Monitoring Committee</gtr:impact><gtr:outcomeId>56e011c66d1c00.88241876</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cuthivac 002 study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Therapeutic vaccine trial database.</gtr:description><gtr:id>F97F2E77-C85C-4FAE-987F-5F5A7C78C062</gtr:id><gtr:impact>Generation of reports for safety monitoring by the Trial Management Group and Independent Data Monitoring Committee</gtr:impact><gtr:outcomeId>56ddc9495110f6.29607228</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CUTHIVTHER study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>The PROUD database was developed by the MRC CTU at UCL data team and allows data to be entered remotely from each of the 13 PROUD study clinics as well as directly at CTU.</gtr:description><gtr:id>A1FF524B-5A8E-4CEA-AFAE-A83EFE9EBEB5</gtr:id><gtr:impact>The database has facilitated real time data entry at each PROUD study clinic and supported data management.</gtr:impact><gtr:outcomeId>54623620ee2d10.83681517</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>PROUD study database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The PROUD study protocol was developed by the MRC CTU at UCL team. The PROUD pilot study protocol defines the following study: PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men.
The protocol includes participant information sheets, informed consent forms and CRFs.</gtr:description><gtr:id>1219B508-F85E-4B5A-A436-3A0AD0999800</gtr:id><gtr:impact>The PROUD pilot study has been conducted under protocol v1.1, 1.2.1, and now 1.3.</gtr:impact><gtr:outcomeId>54623b1511dea5.86233726</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROUD pilot study protocol</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/study_protocol.aspx</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Trial Master File containing Therapeutic vaccine trial protocol, case record forms, meta-data and documents relating to trial management.</gtr:description><gtr:id>4F6251B6-7694-47A1-A532-CB6B93DA19F5</gtr:id><gtr:impact>The documents informed the design of the database, and will be used as a template for future therapeutic vaccine trials.</gtr:impact><gtr:outcomeId>56e01297e629a8.25494884</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CUTHIVTHER Trial Master File</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Report of Phase IIa trial of 3xDNA/1xNYVAC compared to 2xDNA/2xNYVAC that demonstrated benefit of third DNA prime.</gtr:description><gtr:id>F71469D7-61BD-4D6E-9105-F2370BC212D6</gtr:id><gtr:impact>Trials continue with 3xDNA priming</gtr:impact><gtr:outcomeId>YBUPY9fuopM</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>EV03 Clinical Study Report</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The contents of a Clinical Study Report are defined in the International Conference on Harmonisation of technical reports E3 guideline. The report summarises the rationale, design, safety and efficacy data collected, data and trial management structures, as well as the primary and secondary analyses and a line listing of all adverse events that occured during the trial.</gtr:description><gtr:id>CE716A21-AB9B-4E12-8446-1A136CE94279</gtr:id><gtr:impact>Providing the report has helped other groups to draft their reports.</gtr:impact><gtr:outcomeId>5462506b85fb94.72047592</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MucoVac2 Clinical Study Report</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Technology transfer between Imperial College and collaborating institutions within Tanzania (MUHAS, MMRC). Training was carried out involving members of the Imperial and MRC teams.</gtr:description><gtr:id>170937A2-168C-4A14-A769-8FD7AEE2B09B</gtr:id><gtr:impact>The assay will allow the quantitative assessment of an important endpoint in several trials using common reagents and so direct comparison of results across trials which would be extremely valuable.</gtr:impact><gtr:outcomeId>HCHKvf2uGUC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Quantitative assay for the measurement of binding antibodies against CN54rgp140</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The protocol which had been developed for a Phase I clinical trial running in London has been shared with another team within the CUTHIVAC consortium who are planning a trial using the same routes of vaccination in Peru.</gtr:description><gtr:id>4C24CB7C-851F-4830-8417-F127FA650745</gtr:id><gtr:impact>The protocol relates to a clinical trial in healthy humans.</gtr:impact><gtr:outcomeId>FMpiXTSKetg</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Protocol for the CUTHIVAC preventative trial CUTHIVAC_001</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The PROUD study Social Science Advisory Group developed the PROUD one-to-one (or in-depth interview) guide in order to interview participants enrolled in the PROUD pilot study</gtr:description><gtr:id>F7E8DAEB-008D-45E5-AB22-A981D3B1E93B</gtr:id><gtr:impact>The one-to-one guide will be used throughout the pilot study to collect qualitative data on study acceptability, PrEP experiences, PrEP adherence and the impact of PrEP on sexual behaviour</gtr:impact><gtr:outcomeId>54623c9474ebf7.51506714</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROUD study One-to-one Interview guide</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type><gtr:url>http://www.proud.mrc.ac.uk/social_science_study_component.aspx</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The MRC CTU at UCL data team developed a mobile application to allow study participants to remotely access the PROUD participant database from mobile smart devices.</gtr:description><gtr:id>13DF525B-3F8F-48DA-8354-D539C73896E8</gtr:id><gtr:impact>The application was developed in response to participants requests for remote access to the database from smart devices and therefore was a direct response to study participants requests.</gtr:impact><gtr:outcomeId>546237755004a9.69035677</gtr:outcomeId><gtr:title>PROUD participant database mobile application</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>39C71CAE-62C7-4E75-8F9A-027FFCB443AE</gtr:id><gtr:title>Emergent HIV technology: urban Tanzanian women's narratives of medical research, microbicides and sexuality.</gtr:title><gtr:parentPublicationTitle>Culture, health &amp; sexuality</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab512941caeb1aae2accf5cc6383f6ac"><gtr:id>ab512941caeb1aae2accf5cc6383f6ac</gtr:id><gtr:otherNames>Lees S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1369-1058</gtr:issn><gtr:outcomeId>doi_55faa1aa16c0991a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97F4C2B5-F75A-4DDA-A06B-BAB18DEE5702</gtr:id><gtr:title>An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5899f05df03530.51624035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FCAA225-48C8-48F2-8FD3-AD688931D63C</gtr:id><gtr:title>Genital Tract Immunological Markers in Sub-Saharan African Women with Relevance to HIV Risk and Prevention</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6af6898898d5974a6f92bb656f8b213"><gtr:id>e6af6898898d5974a6f92bb656f8b213</gtr:id><gtr:otherNames>Kyongo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd22501e236.01391439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>292D76D8-1D08-43D5-9FAB-3A8D7F937173</gtr:id><gtr:title>Geographical clustering of high risk sexual behaviors in &amp;quot;hot-spots&amp;quot; for HIV and sexually transmitted infections in Kwazulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>544e6975be79e6.98530378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>778F7E4A-1075-40CA-BC97-E4FAB5BE3F20</gtr:id><gtr:title>Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4699885e78f22938054f1dffd0990b"><gtr:id>3a4699885e78f22938054f1dffd0990b</gtr:id><gtr:otherNames>Ladep NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>pm_14129_29_23538773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C3D6148-C51D-4F7A-A65C-03255D46DA61</gtr:id><gtr:title>Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba7304cedf2514ac5d61b9eba0e13eb7"><gtr:id>ba7304cedf2514ac5d61b9eba0e13eb7</gtr:id><gtr:otherNames>McCormack S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>56b1d5519d2325.22416090</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE7A361F-5694-435D-BB2E-B3E83755E132</gtr:id><gtr:title>oral presentation: Engaging Male Partners in Women's Microbicide Use: Evidence from Clinical Trials and Implications for Future Research and Microbicide Introduction (oral abstract session 02 - Microbicides: Male Partner Engagement and Sexual Behaviors)</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef7432fe95d5b4ff650dbadad93250a4"><gtr:id>ef7432fe95d5b4ff650dbadad93250a4</gtr:id><gtr:otherNames>Dayton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5460b7de7ebff0.49179716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEF40025-4295-4CDA-9E26-9659FD2E9773</gtr:id><gtr:title>Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda.</gtr:title><gtr:parentPublicationTitle>Reproductive health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf5c8e0ec541774232c6d8f0012bdce"><gtr:id>3cf5c8e0ec541774232c6d8f0012bdce</gtr:id><gtr:otherNames>Abaasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-4755</gtr:issn><gtr:outcomeId>58c668694c1729.72321987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07EC3C09-44AD-4D01-B108-D0A0714B30E8</gtr:id><gtr:title>Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.</gtr:title><gtr:parentPublicationTitle>Journal of the International Association of Providers of AIDS Care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f9f80fa02f967590b57ba33b56f6ef2"><gtr:id>3f9f80fa02f967590b57ba33b56f6ef2</gtr:id><gtr:otherNames>Mayer K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2325-9574</gtr:issn><gtr:outcomeId>ckgSMcJF1P6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2497C9E-2D7C-42A5-A510-CC039F0DB078</gtr:id><gtr:title>HIV moments and pre-exposure prophylaxis--Authors' reply.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/240e481ef0597cb94a0384928615c218"><gtr:id>240e481ef0597cb94a0384928615c218</gtr:id><gtr:otherNames>Dunn DT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5899f05e3aa864.29287116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C8E94B1-8B8F-412F-A613-F336BAE82AAC</gtr:id><gtr:title>Identifying undiagnosed HIV in men who have sex with men (MSM) by offering HIV home sampling via online gay social media: a service evaluation.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c3014fb05d742a33b2bce4c411aed89"><gtr:id>1c3014fb05d742a33b2bce4c411aed89</gtr:id><gtr:otherNames>Elliot E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>5899f05edf4e49.57433552</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A03C1ED-ADC0-420B-A19A-C0FD128985C0</gtr:id><gtr:title>Shared responsibility for ensuring appropriate management of incidental findings: a case study from South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3bd7edcd755cc6bc526fc8c795402462"><gtr:id>3bd7edcd755cc6bc526fc8c795402462</gtr:id><gtr:otherNames>Sookrajh Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-6800</gtr:issn><gtr:outcomeId>546254330df591.57583368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41061841-06C3-4847-9DE6-575E1FA29F65</gtr:id><gtr:title>The role of progestins in HIV acquisition in young women.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2fb619ef0baba886f95886c59fc5ddf"><gtr:id>f2fb619ef0baba886f95886c59fc5ddf</gtr:id><gtr:otherNames>Ramjee G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>56b1d5516ffdc2.72205117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B67B618-FEC6-432B-936D-D693CEF07A49</gtr:id><gtr:title>Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb0b62134c95c4f61e1eb994bc933c5b"><gtr:id>bb0b62134c95c4f61e1eb994bc933c5b</gtr:id><gtr:otherNames>Girometti N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5899f05f1a0bd1.49520290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04FBD991-E968-4CFE-8D22-A082D45012F1</gtr:id><gtr:title>The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8352078ca98c41558105c7dc74704bb4"><gtr:id>8352078ca98c41558105c7dc74704bb4</gtr:id><gtr:otherNames>Pantazis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>585d54fecc2541.49446594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95A738A5-A8E0-44C9-BA2A-12D74EDDC081</gtr:id><gtr:title>Engaging male partners in women's microbicide use: evidence from clinical trials and implications for future research and microbicide introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c9a53574c8bab233260b7283f1a1653"><gtr:id>4c9a53574c8bab233260b7283f1a1653</gtr:id><gtr:otherNames>Lanham M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>54648917a800b4.71271446</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50FE4932-CA16-46C7-A291-0805016D2CAF</gtr:id><gtr:title>How effective is effective enough? Opinions of potential end-users of microbicides from a rural South African community.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>pm_14129_29_22971053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB075942-CACE-49AC-A590-B7E80A22B7F9</gtr:id><gtr:title>Biomedical prevention: state of the science.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d39f838d6096e14629421fc2350d44"><gtr:id>a5d39f838d6096e14629421fc2350d44</gtr:id><gtr:otherNames>McCormack SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>544fb588a1a933.15031634</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83D71D83-D4FD-4464-B465-3D02F8B93130</gtr:id><gtr:title>Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a24619e8e97fd168eadaf7330b096d1"><gtr:id>7a24619e8e97fd168eadaf7330b096d1</gtr:id><gtr:otherNames>Torrone EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5a9fbb5e696f06.54891249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F1F37FC-00FF-4128-B037-AF68A7ACE98F</gtr:id><gtr:title>Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a8bdd0580cbc8.17447948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDA42147-B7C1-4303-AA86-352B464EB012</gtr:id><gtr:title>Malicious whites, greedy women, and virtuous volunteers: negotiating social relations through clinical trial narratives in South Africa.</gtr:title><gtr:parentPublicationTitle>Medical anthropology quarterly</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bee8f0af3d4cee71c681591ff39fa4e4"><gtr:id>bee8f0af3d4cee71c681591ff39fa4e4</gtr:id><gtr:otherNames>Saethre E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0745-5194</gtr:issn><gtr:outcomeId>pm_14129_29_23674325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93DFF327-84DE-44C6-9713-37EA51AD1A45</gtr:id><gtr:title>Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3cf5c8e0ec541774232c6d8f0012bdce"><gtr:id>3cf5c8e0ec541774232c6d8f0012bdce</gtr:id><gtr:otherNames>Abaasa A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_14129_29_23374729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5767891-10DD-407D-9358-B804497F2788</gtr:id><gtr:title>Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.</gtr:title><gtr:parentPublicationTitle>Developing world bioethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d1bb197cc904bb6e54a57f5b78db9ae"><gtr:id>2d1bb197cc904bb6e54a57f5b78db9ae</gtr:id><gtr:otherNames>Haire B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-8731</gtr:issn><gtr:outcomeId>pm_14129_29_23725227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D906535-2A6C-42DD-AF27-A8167ED8F6F0</gtr:id><gtr:title>Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e592a67027098903f7c40312ef17e6de"><gtr:id>e592a67027098903f7c40312ef17e6de</gtr:id><gtr:otherNames>Morrison CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>56b1d5523c57c4.62705207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72281405-67C0-40F6-8B5E-682246AA93D7</gtr:id><gtr:title>The European preexposure prophylaxis revolution.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02c90827852f58069dfdf54947234e5"><gtr:id>f02c90827852f58069dfdf54947234e5</gtr:id><gtr:otherNames>Cairns G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56b1d55147adb2.65006779</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10B1F591-4E03-40AB-AA09-C0343F781850</gtr:id><gtr:title>Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>54900c66767fb3.61564962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>350F7046-EDA2-44C1-B77E-C256AE1EC88F</gtr:id><gtr:title>Prevalence of Herpes Simplex Virus 2 (HSV-2) infection and associated risk factors in a cohort of HIV negative women in Durban, South Africa.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574366aefb678b01920bb269e942f55b"><gtr:id>574366aefb678b01920bb269e942f55b</gtr:id><gtr:otherNames>Daniels B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>5a2fd569515031.33031891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEA01518-24D9-4F07-8D2A-AE68B2FFF206</gtr:id><gtr:title>Microbicide clinical trial adherence: insights for introduction.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e32eed516dff4b5430c99619f7cdddf7"><gtr:id>e32eed516dff4b5430c99619f7cdddf7</gtr:id><gtr:otherNames>Woodsong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>pm_14129_29_23561044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F97A9ECB-7099-450C-ACE3-6355F26660C6</gtr:id><gtr:title>poster: The UK PROUD PrEP Pilot Study: a baseline analysis.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3217e8e9ffed562462fd4bb598c469b"><gtr:id>f3217e8e9ffed562462fd4bb598c469b</gtr:id><gtr:otherNames>Antonucci S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54623b5ac9c442.64917103</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>410B5D24-7D30-40CC-A7DC-E6ED20047F89</gtr:id><gtr:title>'I heard about this study on the radio': using community radio to strengthen Good Participatory Practice in HIV prevention trials.</gtr:title><gtr:parentPublicationTitle>BMC public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5599b4ef58706984af5f9813297a7701"><gtr:id>5599b4ef58706984af5f9813297a7701</gtr:id><gtr:otherNames>Medeossi BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2458</gtr:issn><gtr:outcomeId>545cdbd0cb8464.94826671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>757E5A08-6B15-483E-B125-58839D6A81A7</gtr:id><gtr:title>High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c466ae98f118459939cc3dd07cd9570d"><gtr:id>c466ae98f118459939cc3dd07cd9570d</gtr:id><gtr:otherNames>Naidoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>doi_55faa1aa16c947a0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6AEF6C4-2EAE-40FE-9982-93B4B99CE29B</gtr:id><gtr:title>Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn><gtr:outcomeId>pm_14129_29_23300336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>149566C7-3A2D-4F11-8C31-9E04DA2731C0</gtr:id><gtr:title>Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d16a0e2cac032025257ed2f44c93f19d"><gtr:id>d16a0e2cac032025257ed2f44c93f19d</gtr:id><gtr:otherNames>Crook AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn><gtr:outcomeId>544fb5886b6026.12952029</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48183261-849E-4412-8F4E-194C36513FC6</gtr:id><gtr:title>Drug Delivery and Development of Anti-HIV Microbicides</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fcc134cff7ca4048dad76a7ecaf0597"><gtr:id>1fcc134cff7ca4048dad76a7ecaf0597</gtr:id><gtr:otherNames>Tolley E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d852c340a835.47771294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B386122-F915-4265-8FC2-5BB6B26F9A60</gtr:id><gtr:title>Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception?</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/440d093fa0202c6122edc3ba737de762"><gtr:id>440d093fa0202c6122edc3ba737de762</gtr:id><gtr:otherNames>Ssali A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546256ac66e9e9.13074195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95B7B575-C2CB-4828-BB32-4AA0A8D3596E</gtr:id><gtr:title>'PROUD Study / PrEP( Pre-exposure prophylaxis for HIV) in the UK'</gtr:title><gtr:parentPublicationTitle>SSHA conference 2013</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b920e79b5706f95651d88ca123e075de"><gtr:id>b920e79b5706f95651d88ca123e075de</gtr:id><gtr:otherNames>Richard Stack (Senior Health Adviser - 56 Dean Street)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54647938f385a9.25233180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90733B59-5FEF-41FA-83B9-71F94827F1AE</gtr:id><gtr:title>Microbicides from a regulatory perspective.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a70acb9aba00435f9a0a4de5461d1ec"><gtr:id>5a70acb9aba00435f9a0a4de5461d1ec</gtr:id><gtr:otherNames>Stone AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>54625508515065.13576160</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F61F65D5-E0F5-43AA-B684-F2564CA7F57F</gtr:id><gtr:title>A longitudinal analysis of the vaginal microbiota and vaginal immune mediators in women from sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b279f694c260d0f902362ffed97982ea"><gtr:id>b279f694c260d0f902362ffed97982ea</gtr:id><gtr:otherNames>Jespers V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa0201d0bae73.99028041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4DBA710-D0EB-40BD-9FF3-44EF251A64F7</gtr:id><gtr:title>Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7517295f45ff7151cd20ed611a3bf8f0"><gtr:id>7517295f45ff7151cd20ed611a3bf8f0</gtr:id><gtr:otherNames>Cambiano V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a8bdd05edc463.28229348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85782EBA-6DC1-41B2-96FD-9DE43BDECC5E</gtr:id><gtr:title>High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/620f7475a9dabd965ead382d723bbe0e"><gtr:id>620f7475a9dabd965ead382d723bbe0e</gtr:id><gtr:otherNames>Mocumbi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a8bdd054f0ed6.90000089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99938175-538D-475A-A1C4-4B0DABD33D5F</gtr:id><gtr:title>Hidden harms: women's narratives of intimate partner violence in a microbicide trial, South Africa.</gtr:title><gtr:parentPublicationTitle>Social science &amp; medicine (1982)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8abf5759c8e695e54167ce931c1417be"><gtr:id>8abf5759c8e695e54167ce931c1417be</gtr:id><gtr:otherNames>Stadler J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-9536</gtr:issn><gtr:outcomeId>545cdfccc55fb0.72564065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48C07724-3A86-41F5-896B-404ABAF0A09F</gtr:id><gtr:title>Bacterial Vaginosis and HIV: An Analysis of the MDP301 Trial</gtr:title><gtr:parentPublicationTitle>AIDS Research and Human Retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c886ea6a1f8c575a3e82ba71366caa9"><gtr:id>7c886ea6a1f8c575a3e82ba71366caa9</gtr:id><gtr:otherNames>Joseph S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545cd34e8141f8.75499253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91DA0BCE-B0ED-405A-A8A2-F9A854D69E45</gtr:id><gtr:title>Welcome to the preexposure prophylaxis revolution.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18f91337e098e5467edbe78d0ef48eb3"><gtr:id>18f91337e098e5467edbe78d0ef48eb3</gtr:id><gtr:otherNames>Baeten J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56b1d55118b456.66678220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4975FFC0-1E13-4C7F-8F06-4BE09D86C19D</gtr:id><gtr:title>Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa.</gtr:title><gtr:parentPublicationTitle>Journal of AIDS &amp; clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a4699885e78f22938054f1dffd0990b"><gtr:id>3a4699885e78f22938054f1dffd0990b</gtr:id><gtr:otherNames>Ladep NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>FDSo6ewQneq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C60FFB05-1935-4022-B685-5417427633E1</gtr:id><gtr:title>Healthcare providers' knowledge of, attitudes to and practice of pre-exposure prophylaxis for HIV infection.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56b1d551cee117.43618008</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C2B6B78-BD9E-487F-B8D7-200B24A1D143</gtr:id><gtr:title>Recent advances in pre-exposure prophylaxis for HIV.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df25c2a5c1c5ecf7fd64b72fc2a20b68"><gtr:id>df25c2a5c1c5ecf7fd64b72fc2a20b68</gtr:id><gtr:otherNames>Desai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>5a8bdd061a0481.85587959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00175C84-A2BC-444F-A64F-BD95DB09BC41</gtr:id><gtr:title>The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89fbf267478571b0dfd2e4f3e548a6ba"><gtr:id>89fbf267478571b0dfd2e4f3e548a6ba</gtr:id><gtr:otherNames>Gafos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>544fb588340573.84380444</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>770DEB88-5B9F-4313-BA2E-CC22679AFCCE</gtr:id><gtr:title>PrEP in Europe - expectations, opportunities and barriers.</gtr:title><gtr:parentPublicationTitle>Journal of the International AIDS Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5d39f838d6096e14629421fc2350d44"><gtr:id>a5d39f838d6096e14629421fc2350d44</gtr:id><gtr:otherNames>McCormack SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1758-2652</gtr:issn><gtr:outcomeId>5899f05eb50214.39733272</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>